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GENERAL INTRODUCTION 
 
n the last decades, endocrine disruption from exposure to environmental 
contaminants has been driven by the considerable work performed on the 
estrogenic system. Nonetheless, the endocrine system is not restricted to the female 
sex hormone axis and several other hormone-driven signaling systems (androgens, 
progestogens, glucocorticoids, retinoids, thyroid hormones, etc.) play crucial roles in 
the maintenance of critical processes such as homeostasis (He et al., 2010), sexual 
development (Li and Kim, 2004), metabolism (Wiegratz and Kuhl, 2006), growth 
(Wightman et al., 2002) and behavior (Mani and Oyola, 2012) throughout the different 
life-stages of numerous species. It is now clear that other branches of the endocrine 
system may also be affected upon exposure to environmental pollutants (Zoeller, 
2007; Jugan et al., 2010), although considerably less information is available on the 
effects of chemicals on these other endocrine systems. This thesis focuses on the 
disruption of the thyroid hormone system, a key player in the regulation of critical 
physiological processes such as growth (Cabello and Wrutniak, 1989), differentiation 
(Tata, 1993), energy metabolism (Cheng et al., 2010), temperature control (Ribeiro, 
2008), brain development and function (Bernal, 2007; Horn and Heuer, 2010; Warner 
and Mittag, 2012), sexual behaviour and fertility (Wagner et al., 2008), heart rate 
(Danzi and Klein, 2012) and other biochemical communication systems of the overall 
endocrine system (De Vito et al., 2011). Disruption of the thyroid hormone system by 
foreign compounds is associated with the increasing incidence of hormone-related 
cancers and developmental defects, such that new European legislation (REACH) 
demands extensive testing of newly marketed compounds. The aim of this thesis was 
to develop and validate functional in vitro bioassays for thyroid hormone receptor-
mediated toxicity, focusing on thyroid hormone receptor interaction. 
 
 
 
 
 
I 
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THYROID HORMONE SYSTEM 
The thyroid hormones (TH), triiodothyronine (T3) and thyroxine (T4) (Figure 1), are 
tyrosine-based hormones produced by the thyroid gland, a butterfly-shaped gland 
which in humans is located in front of the larynx just below the Adams apple. 
 
Figure 1. Chemical structures of the thyroid hormones. A) 3,3’,5-triiodo-L-thyronine (triiodothyronine, T3) 
and B) 3,3’,5,5’-tetraiodo-L- thyronine (thyroxine, T4). 
 
Low circulating TH levels are detected by the hypothalamus, that responds by 
releasing thyrotropin-releasing hormone (TRH). The released TRH, stimulates the 
pituitary gland to produce thyrotropin (also known as thyroid-stimulating hormone, 
TSH). In turn, TSH stimulates the thyroid to produce TH until levels in the blood 
return to normal. Circulating TH exerts a negative feedback control over the 
hypothalamus and pituitary, eventually controlling the release of TRH from the 
hypothalamus and TSH from the pituitary gland. This hormone system that involves 
the hypothalamus, pituitary, and thyroid gland, is known as the hypothalamus-
pituitary-thyroid (HPT) axis (Zoeller et al., 2007) (Figure 2) and regulates TH 
synthesis by a negative feedback regulatory system. 
Thyroid hormones have low water-solubility, and therefore they are chaperoned by 
special TH protein carriers; transthyretin (TTR), thyroxin binding globulin (TBG) and 
albumin, and distributed in this bound form virtually all over the body. Uptake in 
cells of the various tissues proceeds by a process previously assumed as simple 
diffusion (Robbins and Rall, 1960), although these hormones may rather be taken up 
by cells via an energy dependent (adenosine triphosphate, ATP) carrier-mediated 
transport (Hennemann et al., 2001). Following uptake, TH are translocated to the 
nucleus or may interact with non-specific cytosolic binding proteins (CTHBPs). 
Organic ion transport proteins (OATPs) (Hagenbuch, 2007), L-type amino acid 
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transporters (LAT1 and LAT2) (Taylor and Ritchie, 2007), and members of the 
monocarboxylate transporter (MCT) family have also been identified as TH 
membrane transporters (Halestrap, 2012). 
 
 
Figure 2. The Hypothalamic-Pituitary-Thyroid axis, including the roles of thyrotropin releasing hormone 
(TRH), thyroid stimulating hormone (TSH), thyroxine (T4) and triiodothyronine (T3). Other forms of thyroid 
hormones are not included (e.g. T2 and rT3). Minus indicates a negative feedback loop. Reproduced with 
modifications from (Boas et al., 2006).  
 
The thyroid gland secretes mostly T4 that, in target cells, is converted by the so-called 
outer ring deiodinases that remove one of thyroxine's four iodine atoms converting 
the hormone into the highly active T3. Most of the physiological effects induced by TH 
are mediated via the interaction of the active form T3 with specific ligand-dependent 
transcription factors, the thyroid hormone receptors (TRs). Thyroid hormone 
receptors are type II receptors that belong to the large super family of nuclear 
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hormone receptors (Ribeiro et al., 1995) including the steroid, vitamin D and retinoic 
acid receptors and are virtually expressed in all cells. A cell surface thyroid hormone 
receptor (integrin alphavbeta3, !V"3) has also been identified and is known for the less 
studied nongenomic action of the TH (Davis et al., 2011). Integrin binds TH near the 
Arg-Gly-Asp (RGD) recognition site, which propels conformational changes that 
transduce the signal into the mitogen-activated protein kinase (MAPK) activity via 
phospholipase C and PKC (Davis et al., 2000). This enables T4 to activate complex 
intracellular signal transduction cascades, independently of the TRs. 
Thyroid hormone receptors are encoded by two different genes: TR! (NR1A1) and 
TR" (NR1A2), in humans on chromosomes 17 and 3, respectively, and several 
isoforms are generated through alternative splicing (Lazar, 1993). TR!1 and TR!2 are 
expressed predominantly in the central nervous system (CNS), but the TR!2 isoform 
is unable to bind T3, possibly exerting a dominant negative effect on TR!1 and TR" 
(Katz and Lazar, 1993). Instead, TR"1 is mostly prevalent in the liver and kidney and 
TR"2 in the pituitary and hypothalamus (Yen, 2001). Each TR isoform displays tissue 
and developmental stage differences in the level of its expression, suggesting an 
important role in mediating tissue specific effects (Bradley et al., 1989; Furlow and 
Neff, 2006). The receptors can interact with DNA as monomers (TR:DNA), 
homodimers (TR/TR:DNA) or as heterodimers with the retinoid X receptor 
(TR/RXR:DNA), the latter being the major functional form of the receptor. In the 
absence of T3 the receptors recruit cofactors such as the nuclear receptor corepressor 
(N-CoR) or the silencing mediator for retinoid and thyroid receptors (SMRT) that 
modify nearby chromatin to inhibit target gene transcription. Upon binding of T3, the 
corepressors are released and the TR/RXR heterodimer complex now recruits 
coactivators such as the steroid receptor coactivator-1 (SRC-1). This complex forces an 
open configuration on the adjacent chromatin and facilitates RNA polymerase II 
recruitment, thereby activating transcription (Oñate et al., 1995; Koenig, 1998), by 
interacting with DNA sequences usually in the vicinity of target genes known as 
thyroid hormone response elements (TRE) (Desvergne, 1994). Response elements 
consist of one or more short copies of a DNA sequence that matches a consensus 
motif: 5' AGGTCA 3'. Naturally occurring thyroid hormone response elements 
include at least two copies of this motif frequently separated by 4 base pairs arranged 
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as direct repeats (DR-4 elements), palindromes (e.g. AGGTCATGACCT) or inverted 
repeats. The TR DNA-binding domain contains two sets of four cysteine residues 
forming the so-called zinc fingers, which confer specific binding to the response 
elements (Aranda and Pascual, 2001). 
 
DISRUPTION OF THE THYROID HORMONE SYSTEM 
Exposure to a wide range of natural and manufactured chemicals has shown to 
disrupt the TH signaling as seen in early studies reporting unusual thyroid gland 
development in many species of birds and fish (Colborn, 2002). Research with animal 
models (rodent, amphibian and zebrafish) and studies of hypothyroidism, 
hyperthyroidism and other genetic diseases related to the HPT axis have also 
supported concerns about transient and persistent dysregulation of the TH system by 
compounds present in the environment. 
The thyroid hormone system homeostasis is tightly controlled by a complex network 
of regulatory interactions, rendering it almost impossible to isolate a single mode of 
disruption, since this may occur through interactions with the several components of 
the HPT axis. For example, disruption can interfere with TH synthesis, storage and 
release of TH by the thyroid gland (Capen, 1997; Wolff, 1998), protein-bound TH 
distribution (Marchesini et al., 2008), cellular uptake (Chalmers et al., 1993), 
intracellular metabolism (Butt et al., 2011), TH deactivation (Morse et al., 1993), with 
membrane receptors (Sheng et al., 2012) and with the classical nuclear receptors, the 
latter being the main focus of this thesis. 
 
THYROID HORMONE RECEPTOR-MEDIATED DISRUPTION 
The transcriptional control of target genes by the TRs can be considered an important 
checkpoint in the complex network of regulatory mechanisms involving the thyroid 
hormone system, and the endpoint most directly related to altered cellular responses. 
Ultimately, changes in gene expression mediated by the TRs result in observable 
cellular phenotypes that are specific for a given cell type. For example, in response to 
T3 the rat pituitary tumour GH3 cell line proliferates, T3-treated primary cultures of 
cerebellar Purkinje cells show increased dendritic branching (Heuer and Mason, 2003; 
Ibhazehiebo et al., 2011), cardiomyocytes self-organize into three dimensional heart 
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muscle-like structures that alter their contractility properties (Khait and Birla, 2008) 
and primary liver cells show altered expression of metabolic enzymes (Attia et al., 
2010). It should however be emphasized that a multitude of mechanisms are possible 
beyond direct binding to the receptors for disruption of the TH signalling. Compared 
to the estrogen receptor, interactions with the TRs appear to be restricted to chemicals 
with high structural resemblance to the natural hormones, due to the steric limitations 
of the receptor ligand-binding domain (LBD) (DeVito et al., 1999; Zoeller, 2005). As 
described above, upon ligand binding to the TRs corepressors are released and 
coactivators recruited, and chemicals have also been described to act via disruption of 
this interaction (Nguyen et al., 2002). Similarly, disruption of the TR/RXR receptor 
interaction, or direct interactions with the RXR LBD, may also affect a subset of 
important TH target genes in specific tissues (Castillo et al., 2004). Given the 
complexities of the transcriptional control regulated by these receptors, measurement 
of their activity in their native context is highly relevant for predicting any type of TH 
disruption. Detection of TH-like activity and the resulting biological effects can be 
facilitated by in vitro bioassays for TR-mediated effects.  
 
IN VITRO ASSAYS FOR THYROID HORMONE RECEPTOR-MEDIATED ACTIVITY 
Several in vitro bioassays have been developed to determine the ability of compounds 
or mixtures to interfere with the TR. Ligand binding assays typically involve 
measuring the displacement efficiency of radiolabeled T3 bound to TRs overexpressed 
in bacteria or obtained from nuclear extracts of mammalian cells (Kitamura et al., 
2002; Kitamura et al., 2005; You et al., 2006). The relative simplicity of these assays 
renders them quite attractive to determine direct interaction of chemicals with the TRs 
and since these are cell-free assays, there are no issues with cytotoxicity of the 
compound in question. However ligand-binding assays do not predict in vivo agonism 
or antagonism per se and the isolated receptors are not in their native environment 
where proper folding or stability might play a role. Coregulator assays use the 
interaction of domain peptides derived from nuclear receptor coactivators or 
corepressors to the TR LBD, with the recruitment or displacement of these labelled 
peptides followed by fluorescence (Lévy-Bimbot et al., 2012). Due to their potential to 
predict agonism or antagonism based on the pattern of peptide recruitment or 
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displacement these assays have been used for high-throughput screening of 
thousands of compounds (Johnson et al., 2011). However, they present disadvantages 
similar to those already outlined for the ligand binding assays. Furthermore, they 
appear to be relatively insensitive even to T3 with high concentrations up to 10 #M 
often needed to induce a response. An alternative to the ligand binding assays can be 
found in so-called reporter gene assays (Figure 3), which can be either transient or 
stable transfection assays. 
 
Figure 3. Schematic representation of a thyroid hormone receptor-dependent reporter gene cell line. 1) 
Thyroid hormones (TH) are taken up 2) and bind to the thyroid hormone receptor (TR) which may form a 
homodimer with another TR or a heterodimer with a retinoid X receptor (RXR). Corepressors are released, 
followed by 3) coactivators recruitment to the complex bound to a thyroid hormone responsive element 
(TRE) and triggering the 4) expression of the reporter protein (luciferase) that ultimately generate a 
detectable signal (light). 
 
Transient transfection assays usually involve the co-transfection of a TRE-driven 
reporter gene in parallel with a TR-expressing vector if cells lack endogenous 
receptors. These assays can be fairly sensitive and reproducible and have been used to 
demonstrate the effect of compounds like bisphenol A (BPA), its halogenated 
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derivative tetrabromobisphenol A (TBBPA), polychlorinated biphenyls (PCBs), 
polybrominated diphenylethers (PBDEs) and their metabolites on the TR 
transcriptional activity (Zoeller, 2005). Despite their wide acceptance, flexibility, and 
promise, transient transfection assays are relatively expensive and not readily 
adaptable for high-throughput screening due to well-to-well variations across the 
plate, and the fact that the reporter gene is not fully bundled in chromatin like 
endogenous genes. Stable transfection assays circumvent many of the limitations of 
their transient counterparts. Furthermore, development of stable transfection assays 
in cell lines normally responsive to TH, as presented in this thesis, have multiple 
advantages for screening TR-active compounds. For example, such cells express 
endogenous, full-length receptors and a full cohort of the cellular machinery required 
for TH uptake and transcriptional control of target genes.  Use of full length receptors 
also exploits the full range of interactions with a native response element 
configuration via the receptor’s DNA binding domain, and with endogenous co-
regulatory proteins via multiple sites in the amino and carboxytermini of the 
receptors, to allow regulation of a TRE-based reporter embedded in native chromatin. 
 
THESIS SCOPE 
This thesis focuses on the development and validation of functional in vitro bioassays 
for TR-mediated toxicity. This aim can be further specified as follows: 
 
1. Development and validation of in vitro assays for TH disruption; 
2. Identification of new TR agonists and antagonists; 
3. Identification of novel TH target genes; 
4. Elucidation of potential mechanisms of TR-mediated disruption; 
5. Advise on whether predictions can be made based on in vitro studies for in vivo 
disruption of TH action. 
 
In Chapter 1, background information on the topic is given, the aims are defined and 
a short outline of the thesis is presented. 
Chapter 2 describes the development of the GH3.TRE-Luc assay using the rat 
pituitary cell line (GH3), which is also used in the proliferation based T-screen assay 
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(Hohenwarter et al., 1996; Gutleb et al., 2005; Schriks et al., 2006). The assay is based 
on endogenous TRs and proven to be highly sensitive and specific. For example, some 
compounds were identified that were agonists in the T-screen but not in the TR-Luc 
because they do not directly act via the TR. 
The use and validation of this newly developed GH3.TRE-Luc assay in a quantitative 
high-throughput screening platform is described in Chapter 3. The assay proved to be 
quite robust, with excellent performance in an automated 1536-well plate format. The 
LOPAC and NTP 1408 libraries (Library of Pharmacologically Active Compounds 
(1281 chemicals) and National Toxicology Program library (1408 chemicals)) were 
screened and a number of potentially novel agonists and antagonists were identified. 
In Chapter 4 expression levels of thyroid hormone signalling and responsive genes 
upon exposure to TH were revealed by microarray analysis. These data further 
support the validation of the GH3.TRE-Luc cell line as an in vitro model for TR-
mediated disruption of endogenous target genes, and also contribute to the 
understanding of some of the molecular mechanisms triggered by selected TR 
disruptors. 
The expression of the TRs is tissue and life-stage dependent, and therefore 
classification and quantification of TR-isoform specific transactivation allow a better 
translation of in vitro responses to expected in vivo effects (tissue specific effects). 
Chapter 5 describes the development of a stable TR! specific reporter gene cell line 
designated TR!.HeLa-Luc. The developed TR!.HeLa-Luc stable reporter gene line 
adds a new level of specificity, representing an improvement of the available tools for 
in vitro high-throughput assessment of TR subtype-specific activity of drugs and 
environmental pollutants. 
In Chapter 6 concluding remarks as well as some future perspectives are presented on 
the feasibility to predict in vivo thyroid hormone system disruption based on a battery 
of in vitro assays. 
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ABSTRACT 
 
stable luciferase reporter gene assay was developed based on the thyroid 
hormone responsive rat pituitary tumor GH3 cell line that constitutively 
expresses both thyroid hormone receptor isoforms. Stable transfection of the pGL4CP-
SV40-2xtaDR4 construct into the GH3 cells resulted in a highly sensitive cell line 
(GH3.TRE-Luc), which was further optimized into an assay that allowed the detection 
of triiodothyronine (T3) and thyroxine (T4) concentrations in the picomolar range after 
only 24 h of exposure. The greater than 20-fold induction of T3 relative to the solvent 
control is illustrative of the high responsiveness of the system. The assay was 
validated by the quantification of the agonistic effect of the natural hormones (T3 and 
T4), the acetic acid derivatives of T3 (triiodothyroaceticacid, or Triac) and T4 
(tetraiodothyroacetic acid, or Tetrac), hydroxy polybrominated diphenylethers (OH-
PBDEs), hydroxy polychlorinated biphenyls (OH-PCBs) and the antagonistic action of 
sodium arsenite (NaAsO2). The putative antagonist amiodarone, bisphenol A (BPA) 
and its halogenated derivatives (TCBPA and TBBPA) for which effects reported in the 
literature are not consistent, showed comparable dose-response curves with a slight 
agonistic effect (5% of T3-max) followed by a slight antagonistic effect. The magnitude 
and reproducibility of the responses to various compounds confirms this assay as a 
promising tool for the identification and quantification of specific thyroid hormone 
receptor disrupting potency of compounds. 
A 
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INTRODUCTION 
 
ertain environmental pollutants have been shown to display adverse effects on 
the normal function of the endocrine system (Harrison et al., 1997). In 
particular, adverse effects on the thyroid endocrine axis are very important to assess 
since the thyroid hormones, triiodothyronine and thyroxine (T3 and T4), play a crucial 
role in growth, development and energy homeostasis (Silva, 2001; Yen, 2001). Thyroid 
hormones induce their physiological effects through the thyroid hormone receptors 
(TRs) (Samuels and Tsai, 1974), which belong to the large super family of nuclear 
hormone receptors including the steroid, vitamin D and retinoic acid receptors (Beato 
et al., 1995). These receptors are ligand-dependent transcription factors able to interact 
with DNA sequences known as response elements, usually located in the vicinity of 
target genes (Desvergne, 1994). Several environmental contaminants and their 
metabolites, to which humans are routinely and involuntarily exposed, can disturb 
the thyroid hormone endocrine system (Crofton, 2008) at several different pre-
receptor points of action: synthesis, transport, metabolism and cellular uptake. These 
different targets are the most widely studied for disruption to date (Brouwer et al., 
1998; Marchesini et al., 2008; McKinney and Waller, 1994; Schmutzler et al., 2007). For 
instance, the polychlorinated biphenyls (PCBs) and more specifically the hydroxyl-
lated PCB-metabolites (OH-PCBs) that structurally mimic the thyroid hormones have 
both high affinity for thyroid hormone binding proteins and thyroid hormone 
metabolizing enzymes (Cheek et al., 1999; Marchesini et al., 2008; Meerts et al., 2002; 
Miyazaki et al., 2004; Schuur et al., 1998), although some studies have shown that 
these chemicals are also able to disturb thyroid hormone receptor-mediated gene 
transcription (Bogazzi et al., 2003; Miyazaki et al., 2008). The hydroxylated metabo-
lites of the flame-retardants polybrominated diphenylethers (PBDEs) have been 
shown to interfere with the thyroid hormone system as well (Hamers et al., 2006, 
2008). If these environmental pollutants act as thyroid hormone analogs (Zoeller, 
2007) by binding to thyroid hormone receptors, they may directly disrupt normal 
thyroid hormone signaling in target cells. 
Considering the large number of natural and manufactured chemicals that may 
C 
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disrupt the thyroid hormone mode of action, EPA’s endocrine disruption screening 
program (EDSP) requires Tier 1 screening information on estrogen-, androgen-, and 
thyroid-mediated endocrine effects. Currently the EDSP Tier 1 screening battery 
includes the amphibian metamorphosis assay (using the frog Xenopus laevis). A 
defined testing program as described by EPA does not apply in Europe; testing is 
carried out on a case-by-case basis. Under the regulatory system for chemicals 
controlled by the European Chemical Agency (ECHA), Registration, Evaluation and 
Authorization of Chemicals (REACH), it is stated that when a clear link between 
serious adverse effects and an endocrine mode of action can be established, the 
substance may be included in Annex XIV of substances subject to the authorization 
procedure. The guidance prepared by ECHA contains testing strategies, including 
evaluation of non-testing data, in vitro screening data and in vivo screening and testing 
data. However, in vitro screening assays as lower tier tests for identification of a 
potential thyroid hormone disrupting mode of action do not yet exist therefore this 
evaluation of chemicals is mainly based on the amphibian metamorphosis assay 
(Opitz et al., 2005), requiring a large number of test individuals. One key point of the 
new legislation is the reduction of vertebrate studies, which should only be used if no 
other suitable assays exist. Great effort has been put into the development of 
integrated and intelligent testing strategies for evaluation of the potential adverse 
effects of thyroid disrupting compounds, such as the use of (quantitative) structure–
activity (QSAR) relationships as well as in vitro assays which are expected to provide 
useful information on the mechanism of action of many different chemicals. The 
extraordinarily high number of chemicals to be assessed within a few years (about 
30,000 substances are currently marketed at volumes greater than 1 ton/year) places a 
premium on specific, functional and high-throughput in vitro screening systems. 
Although some promising assays have been developed for interference with thyroid 
hormone transport (Marchesini et al., 2008), to our knowledge, there are no rapid and 
specific tests enabling high-throughput detection of compounds directly activating or 
inhibiting the thyroid hormone receptor. 
A number of rat pituitary tumor cell lines (GH1, GH3 and the derivatives GC and 
GH4C1) cloned from the same rat pituitary tumor (Tashjian, 1968), display an 
increased level of cell proliferation and growth hormone secretion in response to 
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physiologic levels of thyroid hormones (Hinkle, 1986; Samuels et al., 1973; Seo et al., 
1977). Based on the thyroid hormone-induced proliferation of the rat pituitary tumor 
cell line GH3, the T-screen has been developed to study the interference of 
compounds with thyroid hormone action (Gutleb et al., 2005; Hohenwarter et al., 
1996; Schriks et al., 2006). Although the T-screen has proven to successfully predict the 
effects of some thyroid hormone disrupting chemicals, the assay is relatively time 
consuming and not entirely specific since effects on cell proliferation through non-
thyroid receptor-mediated mechanisms cannot be excluded. 
This study describes the development and chemical validation of a stable thyroid 
hormone receptor specific reporter gene assay based on the GH3 cell line. The 
validation of the assay was performed using the natural hormones T3 and T4 and their 
metabolites Triac and Tetrac which are pharmaceutical structural analogs that have 
also been used in TH replacement therapy, all shown to be active in the T-screen 
(Gutleb et al., 2005). Amiodarone (Norman and Lavin, 1989) and sodium arsenite 
(Davey et al., 2008) were used as model compounds to demonstrate antagonistic 
behavior on the TR-mediated gene induction mechanism. As model toxic compounds 
we have chosen to evaluate chemicals that structurally resemble thyroid hormones: T3 
and T4-like hydroxylated polybrominated diphenylethers (4-OH-BDE 69 and 4-OH-
BDE 121, respectively) and the T3-like hydroxylated polychlorinated biphenyls 4-OH-
PCB 69 and 4-OH-PCB 106. In addition, bisphenol A (BPA), tetrabromobisphenol A 
(TBBPA) and tetrachlorobisphenol A (TCBPA) were also included because of the 
apparent conflicting reports on their thyroid hormone receptor-mediated activity in 
different in vitro assays (Kitamura et al., 2002, 2005b; Moriyama et al., 2002; Schriks et 
al., 2006). 
Our results demonstrate that the newly developed GH3.TRE-Luc cell line is a 
promising tool for high-throughput in vitro screening, allowing simple, rapid, and 
specific testing of thyroid hormone receptor agonists and antagonists. 
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MATERIALS AND METHODS 
 
Chemicals. All chemicals were of ≥98% purity unless stated otherwise. 3,3",5-triiodo-
L-thyronine (T3, CAS no. 6893-02-3), 3,3",5,5’-tetraiodo-L-thyronine (T4, CAS no. 51-48-
9), 3,5,3',5'-tetraiodothyroacetic acid (Tetrac, CAS no. 67-30-1), 3,5,3'-triiodothyroacetic 
acid (Triac, CAS no. 51-24-1), 2,2-bis(4-hydroxyphenyl)propane (BPA, CAS no. 80-05-
7), 2,2-bis(4-hydroxy-3,5-dichlorophenyl)propane (TCBPA, CAS no. 79-95-8), 4,4'-
propane-2,2-diylbis(2,6-dibromophenol) (TBBPA, CAS no. 79-94-7), 2-butyl-3-benzo- 
furanyl-4-(2-(diethylamino)ethoxy)-3,5-diiodophenyl ketone hydrochloride (Amio- 
darone hydrochloride, CAS no. 19774-82-4) and sodium arsenite (CAS no. 7784-46-5) 
were purchased from Sigma-Aldrich Chemie B.V. (Zwijndrecht, Netherlands). T3-like 
4’-hydroxy-2,3’,4,6-tetrabromodiphenylether (4-OH-BDE 69, CAS no. 218303-98-1) 
and the T4-like 4’-hydroxy-2,3’,4,5’,6-pentabromodiphenylether (4-OH-BDE 121, CAS 
no. 91370-78-4) were kindly provided by Åke Bergman (Stockholm University, 
Sweden) and synthesized as described (Marsh et al., 1998). T3-like 4-hydroxy-2',3,4',6'-
tetrachlorobiphenyl (4-OH-PCB 69, CAS no. 189578-00-5) and T3-like 4-hydroxy-
2',3,3',4',5'-pentachlorobiphenyl (4-OH-PCB 106, CAS no. 192190-09-3) were obtained 
from AccuStandard (New Haven, USA). All compounds were dissolved in 
dimethylsulfoxide (DMSO, 99.9%; Acros Organics, Geel, Belgium) and kept at room 
temperature in the dark. Figure 1 illustrates the chemical structure of the compounds 
used in this study. 
 
Plasmids. The plasmids pBluescript SK- (Genbank Accession# X52324) and pCI-neo 
(Genbank Accession# U47120) were purchased from Promega (Madison, WI). The 
vectors pCS2-#galactosidase and pCS-GFP3 were a kind gift from Dave Turner 
(University of Michigan, USA) and Enrique Amaya (University of Manchester, UK), 
respectively. The thyroid hormone receptor-regulated luciferase reporter plasmid 
pGL4CP-SV40-2xtaDR4 contains two thyroid hormone response elements upstream 
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Figure 1. Chemical structures of A) 3,3",5-triiodo-L-thyronine (T3), B) 3,3",5,5’-tetraiodo-L-thyronine (T4), C) 
3,5,3'-triiodothyroacetic acid (Triac), D) 3,5,3',5'-tetraiodothyroacetic acid (Tetrac), E) T3-like 4’-hydroxy-
2,3’,4,6-tetrabromodiphenylether (4-OH-BDE 69), F) T4-like 4’-hydroxy-2,3’,4,5’,6-pentabromodiphenylether 
(4-OH-BDE 121), G) T3-like 4-hydroxy-2',3,4',6'-tetrachlorobiphenyl (4-OH-PCB 69), H) T3-like 4-hydroxy-
2',3,3',4',5'-pentachlorobiphenyl (4-OH-PCB 106), I) 2,2-bis(4-hydroxy-3,5-dichlorophenyl)propane (TCBPA), 
J) 4,4'-propane-2,2-diylbis(2,6-dibromophenol) (TBBPA), K) 2,2-bis(4-hydroxyphenyl)propane (BPA), L) 2-
butyl-3-benzofuranyl-4-(2-(diethylamino)ethoxy)-3,5-diiodophenyl ketone hydrochloride (amiodarone 
hydrochloride). 
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of an SV40 minimal promoter driving expression of a modified firefly luciferase 
reporter. The SV40 minimal promoter was amplified by PCR from the pGL3-Promoter 
plasmid (Genbank Accession# U47298; Promega, Madison, WI) using the SV40-Up 
(gatcAGATCTCCTAGGAAGCTTtgcatctcaattagtcagcaaccatagtc) and SV40-Dn (aag 
ctttttgcaaaagcctaggcctc) primers, digested with Bgl II and ligated into the 
pGL4.12(luc2CP) vector (Genbank Accession#AY738224; Promega, Madison, WI) 
which was digested with HindIII, filled with DNA polymerase I Klenow fragment 
and redigested with Bgl II. The pGL4CP-SV40-2xtaDR4 plasmid was created by 
ligating a 2xtaDR4 adapter (2xtaDR4-Top: tcgagTAAGGTCATTTAAGGTCATTTAA 
GGTCATTTAAGGTCAa and 2xtaDR4-Btm: gatctTGACCTTAAATGACCTTAAATG 
ACCTTAAATGACCTTAc) that contains two tandem consensus thyroid response 
elements (direct repeats of the consensus AGGTCA halfsite sequence, separated by 
the tetranucleotide sequence TTTA) between the Xho I and Bgl II sites of pGL4CP-
SV40. Sequence data for pGL4CP-SV40 and the pGL4CP-SV40-2xtaDR4 can be found 
at www.mic.ucdavis.edu/privalsky/Sequences/pGL4CPseries/pGL4_series. 
 
Transfections. The rat pituitary tumor GH3 cells were routinely sub-cultured once a 
week in fresh 75 cm2 culture flasks (Corning, Schiphol-Rijk, The Netherlands), in a 
humid atmosphere at 37°C and 95% air/5% CO2 and in Dulbecco’s Modified Eagle’s 
medium/ Ham’s F12 (DMEM:F12, Gibco, Paisley, Scotland) supplemented with 10% 
Fetal Calf Serum (FCS, Gibco, Paisley, Scotland). Twenty-four hours before 
transfection, GH3 cells were seeded into 12-well plates (Corning, Schiphol-Rijk, The 
Netherlands), at a density of 1.6×105 cells per well in regular growth medium. 
Transient transfections were performed with Lipofectamine 2000 according to the 
manufacturer’s instruction (Invitrogen, Paisley, Scotland). Transfection optimization 
was performed with increasing amounts of DNA (100 ng pCS2-#galactosidase, 100 ng 
pCS-GFP3 and 200 to 800 ng pBluescript SK-) and 2 to 8 $l of Lipofectamine 2000 (100 
ng pCS2 cbgal, 100 ng pCS3 GFP and 600 ng pBluescript SK). Cells were then allowed 
to recover for 6 h after transfection in DMEM:F12+10% FCS for 48 h. Cells were then 
visually inspected under a microscope for GFP expression and harvested to measure 
β-galactosidase activity. 
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To create the stable cell line, cells were passaged 1:10 into fresh growth medium 24 h 
after transfection. Forty-eight hours post-transfection, standard growth medium was 
replaced with selective medium containing 320 $g/ml of Geneticin (Gibco, Paisley, 
Scotland). 
 
Screening of GH3.TRE-Luc clones. Single Geneticin resistant colonies were 
harvested using cloning rings and genomic DNA was isolated with GenElute 
Mammalian Genomic DNA Purification Kit according to the manufacturer’s 
instruction (Sigma-Aldrich Corp, St. Louis, MO, USA). A nested-PCR targeting a 480 
bp fragment of the luc4CP reporter gene was performed with the following primers: 
sense1 5"-CTTCGTGACTTCCCATTTGC-3"; antisense 5"-GCCTCACCTACCTCCTTG 
CT-3" and sense2 5"-ACTTGATCTGCGGCTTTCG-3". The nested-PCR was carried out 
with a preliminary incubation step at 94°C for 10 min, 35 cycles of denaturation at 
94°C for 60 s, annealing at 56.6°C/55.3°C for 30 s, extension at 72°C for 30 s then 
finally followed by an elongation step at 72°C for 10 min. 
PCR positive clones were screened for T3-induced luciferase activity in triplicate 
including the vehicle control. Twenty-four hours before plating, standard culture 
medium was replaced by serum free medium PCM as originally described (Sirbasku 
et al., 1991). Cells were plated at 100% confluency in white clear bottom 96-well 
microplate (PerkinElmer, Groningen, The Netherlands), exposed to T3 for 24 h and 
luciferase activity was assayed with the Luciferase Assay System (Promega, Madison, 
WI, USA). Total protein content was assessed in parallel with the BCA Protein Assay 
Kit (Pierce, Rockford, IL, USA) and used to normalize luciferase measurements. 
 
Luciferase reporter gene assay using GH3.TRE-Luc cells line. GH3.TRE-Luc cells 
were seeded at 80% confluency in 75 cm2 culture flasks (Corning, Schiphol-Rijk, The 
Netherlands) in regular growth medium. Twenty-four hours later, growth medium 
was replaced by PCM for an additional period of 24 h. Cells were then collected by 
scraping and seeded into 96-well plates at a density of 3×104 cells per well and 
incubated for 24 h in the presence (0.25 nM) or absence of T3, with or without the 
indicated test chemical in DMSO. The DMSO concentration in 200 $l of exposure 
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medium was always the same for all exposures within an experiment and always kept 
≤0.5% (v/v) to avoid cytotoxicity. A full T3 standard curve comprising a concentration 
range from 0 to 1000 nM, was included on each exposure plate. 
Cell viability in each well was determined by measuring total cellular metabolic 
activity using the reduction of resazurine to the fluorescent resorufin as previously 
described (O'Brien et al., 2000), (Schriks et al., 2006). Following the 24 h exposure 
described above, 8 "l of a 400 "M resazurine (Sigma-Aldrich Chemie B.V., 
Zwijndrecht, Netherlands) solution was added to each well. After four hours of 
incubation in the dark (37°C; 95% air/5% CO2) fluorescence was measured at #ex=530 
nm and #em=590 nm (Milli-pore Cytofluor 2350 Fluorescence Measurement System). 
Luciferase activity was then measured on lysed cells in a microplate luminometer 
with two injectors (Thermo LabSystems luminoskan Ascent), as previously described 
(Murk et al., 1998). All exposures were performed in triplicate and every assay was 
repeated at least three times. 
 
Data and statistical analysis. Results show the representative of three independent 
experiments. Data correspond to the mean ± standard deviation of triplicate 
measurements expressed as relative light units, normalized for viable cell number 
(RLU/RFU) if statistically significant differences were measured via the resazurine 
assay. 
The dose-response curves were characterized by the half maximal effect concentration 
(EC50) and the EC10, the concentration needed to induce the same effect as 10% of the 
E2-maximum induction. The relative potency (RP) of each compound was determined 
as the ratio between the EC50 of T3 and the EC50 of the compound. When the maximum 
induction was less than 50% of the T3-maximum, the RP was calculated with the 
respective EC10 value. Compounds are considered to be not active when the response 
is lower than the vehicle control plus 2× the standard deviation, which was defined as 
limit of detection (Veld et al, 2006). 
Percentages of maximal luciferase induction for each test compound were calculated 
by setting luciferase response to solvent control (DMSO) as 0% and the maximum 
luciferase induction by 10 nM T3 as 100%. The induction factor is calculated as the 
highest response divided by the response of the solvent control, after subtraction of 
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the plate background. 
Statistical significance was tested by one-way analysis of variance (ANOVA), 
followed by Student-Newman-Keuls test. Differences were considered significant at p 
< 0.05. Curve fitting, EC50, EC10 and IC50 values were computed using GraphPad Prism 
version 5 for Mac OSX (GraphPad Software, San Diego California USA, 
www.graphpad.com). 
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RESULTS 
 
Validation of the TRE based luciferase reporter gene assay with natural and 
synthetic thyroid hormones. All experimental conditions for culturing, transfecting, 
shifting to serum free media and measuring luciferase activity with the stable GH3 
cells were thoroughly optimized before the final method for transfection and 
screening compounds was decided upon. For instance, transfection efficiency is 
optimal when transfecting GH3 cells with 2 $l/well of Lipofectamine 2000 and 800 ng 
of total DNA (Figure 2). 
 
 
Figure 2. Results of transfection optimization prior to the development of stable clones. Transient 
transfection efficiency determined through visual inspection under the microscope of GFP-positive cells 
(representative microscopic fields of cells) and β-galactosidase activity (OD550/min) measured 48 h after 
transfection with increasing amounts of A) DNA and B) Lipofectamine 2000. For details see materials and 
methods section. 
 
When testing TR-mediated luciferase induction by compounds it is particularly 
important to use serum free PCM medium instead of culture medium supplemented 
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with stripped serum to avoid background induction by low levels of thyroid 
hormones that might still be in the serum (Figure 3). 
 
 
Figure 3. Effect of exposure medium on luciferase induction by 100 nM T3 relative to solvent control 
(DMSO) in stably transfected GH3.TRE-Luc cells exposed for 24 h in 12-wells tissue culture plates. 
Exposure media tested: Dulbecco’s Modified Eagle’s medium/ Ham’s F12 (DMEM:F12) supplemented with 
either regular (FCS) or stripped 10% Fetal Calf Serum (str.FCS), reduced serum medium (Opti-MEM I) or 
serum-free medium (PCM). Results are mean ± SD of triplicates, corrected for viable cell numbers. 
 
For quantification of cell proliferation the resazurine method was preferred as it 
proved to be more sensitive than total protein (Figure 4A). Also, 24 h of exposure to 
increasing concentrations of T3 barely induced cell proliferation as opposed to 96 h 
exposure in the T-screen (Figure 4B). 
GH3.TRE-Luc cells stably transfected with the expression vector pCI-neo and the 
reporter plasmid pGL4CP-SV40-2xtaDR4, were obtained by antibiotic selection and 
further tested to select lines with the best inducibility. The dose-dependent response 
of these cells to T3 and T4 is shown in Figure 5A. T3 was almost 100 times more potent 
than T4 with an EC50 of 0.1 ± 0.02 nM (n=3) and 9 nM ± 0.4 nM (n=3) respectively. The 
maximum T3-induced effect was reached at 10 nM. T4 reached its maximum induction 
at 100 nM, which is 90% of the T3-maximum response. The average coefficient of 
variation (CV) of triplicate measurements is 5%. 
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Figure 4. Effect of T3 on GH3.TRE-Luc cells proliferation in serum free medium (PCM). A) Determined after 
24 h by the resazurine method and expressed as relative fluorescence units (!, left axis), and measured by 
the BCA protein assay expressed as total protein (", right axis). B) Determined with the resazurine method 
after 24 h (!) and 96 h ("). Error bars indicate SD of triplicate data points. 
 
 
Figure 5. GH3.TRE-Luc induction after 24 h exposure to A) T3 (() and T4 (○), B) Triac (() and Tetrac (○). 
Results (mean ± SD of triplicate data points) are expressed as relative light units (RLU) for luciferase 
activity per relative fluorescence units (RFU) for normalization of viable cell number; absolute values for 
vehicle control (DMSO) from each plate were subtracted from values obtained from each ligand treated 
well. 
 
Chapter 2 
 44 
The acetic acid derivative of T3, Triac, was as effective as T3 with an EC50 of 0.1 ± 0.04 
nM (n=3) and inducing the same maximal luciferase activity at 100 nM (Figure 5B). 
Tetrac was approximately as effective as T4, with an EC50 of 14.2 ± 0.8 nM (n=3) and a 
maximum response of approximately 80% of the T3-maximum (Figure 5B). Taken 
together, these results demonstrate the sensitivity and robust inducibility of the 
system for detecting thyroid hormone receptor agonists. 
 
Effects of compounds that antagonize TH action: amiodarone and sodium 
arsenite. Contrary to previous findings (Schriks et al., 2006), amiodarone did not 
antagonize the response induced by 0.25 nM of T3 (Figure 6A). Amiodarone alone had 
no effect (data not shown), but at concentrations up to 1 $M the T3-induced response 
is significantly increased. At higher concentrations, as the viability of the cells is 
reduced, the response decreases. Visible cytotoxicity occurs at 10 $M. However, 
consistent with other reports (Davey et al., 2008), sodium arsenite clearly inhibits 
luciferase activity induced by 0.25 nM of T3 (Figure 6B). The IC50 was 3 $M and 
concentrations of sodium arsenite above 100 $M  completely antagonize the T3-
induced luciferase activity without any signs of cytotoxicity upon visual inspection 
and as indicated by the resazurine assay. 
 
Effects of environmental compounds in GH3.TRE-Luc cells. The T3-like (4-OH-BDE 
69) and T4-like OH-BDEs (4-OH-BDE 121) were able to induce luciferase activity in the 
GH3.TRE.Luc cells (Figure 7A), although with approximately 104 times lower potency 
and 5 times lower maximal induction for the T3-like OH-BDE when compared to T3 
(Table 1). In addition, the T3-like OH-PCBs (4-OH-PCB 69 and 4-OH-PCB 106) clearly 
induced luciferase activity in a dose-related manner (Figure 7B), and their respective 
relative potencies and maximal induction are roughly in the same order of magnitude 
as the two OH-BDEs tested (Table 1). 
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Figure 6. GH3.TRE-Luc induction after 24 h exposure, in the presence of 0.25 nM of T3, to A) amiodarone 
and B) sodium arsenite. Luciferase activity ((, left axis) relative to T3 maximal induction (at 10 nM set at 
100%, DMSO set at 0%) and the number of viable cells (!, right axis) expressed as relative fluorescence 
units (RFU). Error bars indicate SD of triplicate data points. *Significantly different from control (*p < 0.05, 
**p < 0.01). † = visible cytotoxicity. 
 
Figure 7. GH3.TRE-Luc induction after 24 h exposure to A) T3-like 4-OH-BDE 69 (() and T4-like 4-OH-BDE 
121 (○), B) T3-like 4-OH-PCB 69 (() and 4-OH-PCB 106 (○). Luciferase activity relative to T3 maximal 
induction (at 10 nM set at 100%, DMSO set at 0%). Error bars indicate SD of triplicate data points. 
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Table 1. Effects of compounds in the stably transfected GH3.TRE-Luc reporter gene assay. Maximal 
Induction (%) expressed relative to T3 (10 nM) set at 100%. For three individual experiments, the Relative 
Potency (RP) was calculated as the ratio of the half maximal effective concentration (EC50) for T3 with each 
chemical. Chemicals not inducing up to 50% of T3 maximal effective concentration have RP based on EC10 
levels and given between brackets (n.a. = not active). BDE 69, BDE 121, PCB 69, PCB 106. BPA, TBBPA and 
TCBPA do not induce a significant effect. 
 
Compound EC10 (nM) EC50 (nM) RP EC50/EC50 (10) Max. luciferase Induction (%) 
T3 0.01 0.1 ± 0.02 1 100 (10 nM) 
T4 - 9.1 ± 0.4 1×10-02 94 
Triac - 0.1 ± 0.04 1 100 
Tetrac - 14.2 ± 0.8 7×10-03 82 
T3-like 4-OH-BDE 69 61 ± 11 - (2×10-04) 22 
T4-like 4-OH-BDE 121 460 ± 23 - (3×10-05) 7 
T3-like 4-OH-PCB 69 23 ± 7 - (6×10-04) 13 
T3-like 4-OH-PCB 106 290 ± 15 - (5×10-05) 4 
 
BPA (Figure 8), TCBPA and TBBPA (Figure 9A and 9B, respectively) induced a 
similar and very characteristic effect. After an initial slight increase of the luciferase 
activity up to 1 $M (approximately 5% of T3-maximum induction), the luciferase 
induction then decreases again at higher concentrations. However, at concentrations 
above 10 $M for TCBPA and TBBPA and 100 $M for BPA visible cytotoxicity occurs. 
 
 
Figure 8. GH3.TRE-Luc induction after 24 h exposure to BPA with (() and without (○) 0.25 nM T3. 
Luciferase activity (left axis) as relative percentage of T3 maximal induction (at 10 nM set at 100%, DMSO 
set at 0%) and the number of viable cells (!, right axis) expressed as relative fluorescence units (RFU). Error 
bars were calculated as SD of triplicate data points. 
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Figure 9. GH3.TRE-Luc induction after 24 h exposure, in the presence of 0.25 nM of T3, to A) TCBPA and B) 
TBBPA. Luciferase activity ((, left axis) as relative percentage of T3 maximal induction (at 10 nM set at 
100%, DMSO set at 0%) and the number of viable cells (!, right axis) expressed as relative fluorescence 
units (RFU). Without T3 both compounds did not induce a response. Error bars indicate SD of triplicate data 
points. † = visible cytotoxicity. 
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DISCUSSION 
 
n the present study, we developed and validated a stable in vitro reporter gene 
assay that enables rapid and specific quantification of thyroid hormone receptor-
mediated activity of hormones such as T3 or T4, their structural analogs and 
environmentally relevant contaminants. The bioassay was established using the rat 
pituitary tumor cell line GH3 that constitutively expresses both thyroid hormone 
receptor isoforms (Lazar, 1990). The GH3 cells thyroid hormone-induced proliferation 
is used as basis for the T-screen, a cell-based proliferation assay applied in the 
investigation of the interference of compounds with thyroid receptor-mediated 
cellular responses. However, as with other proliferation assays, the relatively time 
consuming T-screen bears the major drawback of assuming that cell proliferation is an 
entirely genomic thyroid hormone receptor-mediated mechanism. To be able to 
measure a thyroid receptor-specific end point in a high-throughput configuration, the 
GH3 cell line was stably transfected with a thyroid hormone response element 
regulated luciferase reporter gene enabling the detection of T3 concentrations in the 
picomolar range within only 24 h of exposure, rather than the 96 h exposure used in 
the T-screen. Although 24 h of exposure to even high concentrations of T3 only 
minimally induced cell proliferation (Figure 4A), the luciferase response was 
normalized for cell viability determined as the reduction of resazurine to resorufin. 
The resazurine method, which gives an immediate indication of cytotoxicity, is a more 
sensitive measure of cell viability than total protein quantification (Figure 4B). 
Moreover, it can be performed in the same wells since it doesn’t require cell lysis and 
there isn’t any interference with the luciferase measurement, allowing further 
reduction of the time required to run the assay. The maximal induction factor 
obtained with the newly developed GH3.TRE-Luc cells (23-fold at 10 nM, Figure 5A) 
with an average CV of 5% provides a good dynamic range to detect agonists, 
antagonists and potentiators. By comparison, using the same cell line, the previously 
reported maximum induction factors upon T3-exposure were only 3.5-fold (Gauger et 
al., 2007; You et al., 2006) and 4-fold (Davey et al., 2008) in a transient transfection 
assay format. The use of the destabilized luciferase in our assay may contribute to the 
I 
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high inducibility, as this strongly reduces the background activity after 24 h (Almond 
et al., 2004). The relative potency of natural thyroid hormones and the acetic acid 
derivatives of T3 and T4 (Triac and Tetrac) for inducing luciferase activity is highly 
consistent with previous reports; i.e. T3 > Triac > T4 > Tetrac (Cheek et al., 1999; Gutleb 
et al., 2005; Halpern and Hinkle, 1984), (Samuels et al., 1979). 
We also examined the ability of the assay to detect compounds that antagonize TR-
mediated transcriptional activity. The presumed antagonist amiodarone (Hamers et 
al., 2006; Norman and Lavin, 1989; Schriks et al., 2006) significantly increased the T3-
induced thyroid receptor-mediated luciferase activity at concentrations below 1 $M, 
accompanied by a statistically significant decrease in cell viability (Figure 6A). At 
higher concentrations the luciferase activity was reduced in parallel with the number 
of viable cells. Above 10 $M cytotoxicity became visible. This finding demonstrates 
the importance of a receptor-specific assay, as inhibition of T3-dependent cell 
proliferation can be due to cytotoxicity as well. Other reports, however, show that 
amiodarone’s antagonistic behavior is actually mediated through its major metabolite, 
desethylamiodarone (Bakker et al., 1994; van Beeren et al., 2003). The ambiguous 
effect of amiodarone in the GH3.TRE-Luc assay compared with previously reported 
effects, suggests a different mechanism of action for this chemical other than a 
standard thyroid receptor agonism or antagonism. Recently we have demonstrated 
the ability of amiodarone to interfere with cellular efflux pumps (in prep.), which 
could account for the initial increase in luciferase response in the presence of T3, until 
at higher concentrations the compound becomes cytotoxic. Taking all into account 
amiodarone can hardly be used as a suitable antagonist, and unfortunately 
desethylamiodarone cannot easily be obtained. On the other hand, sodium arsenite 
was able to inhibit the thyroid receptor-mediated luciferase expression at non-
cytotoxic concentrations (Figure 6B). This effect is in accordance with previous studies 
reporting that sodium arsenite acts as a strong endocrine disruptor by altering gene 
regulation by several nuclear receptors, including the thyroid hormone receptor 
(Davey et al., 2007; Davey et al., 2008; Kaltreider et al., 2001; Rosenblatt and Burnstein, 
2009) suggesting a common inhibitory mechanism of action for this family of 
receptors. 
We also examined the thyroid hormone receptor disrupting activity of hydroxyl 
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metabolites of PCBs and BDEs, which are important environmental contaminants. The 
relative potencies of the synthetic T3- and T4-like OH-BDEs tested in the GH3.TRE-Luc 
cells were in the same order of magnitude of those reported for the T-screen (Schriks 
et al., 2006) and in good agreement with a previously reported thyroid receptor 
binding assay (Marsh et al., 1998). Like the OH-BDEs, both the OH-PCB 69 and OH-
PCB 106 showed a dose-dependent agonistic response, which is consistent with 
previously reported results (Ghisari and Bonefeld-Jorgensen, 2005; Kitamura et al., 
2005a; You et al., 2006). Interestingly, the same two chemicals have shown to 
antagonize thyroid receptor-mediated luciferase induction in different cell-based 
assays (Iwasaki et al., 2002; Miyazaki et al., 2004). The apparent discrepancy found, 
for this chemical family and others, may be a reflection of their tissue and receptor 
subtype specific mode of action. The GH3 cells used here are well characterized and 
are known to express both thyroid receptor isoforms as well as their heterodimer 
partners and respective cofactors; these and other unknown transcription factors may 
be absent in other cell-based systems yielding completely different transcriptional 
outcomes. It would not be surprising if the cell type selective actions of these 
environmental compounds are reminiscent of the actions of the so-called selective 
estrogen receptor modulators (SERMs), whose agonist or antagonistic activities 
depend at least in part on qualitative and quantitative differences in receptor 
coactivators and corepressors in different cell types (Smith and O'Malley, 2004). 
As was to be expected, the parent (non-hydroxylated) BDEs and PCBs were not able 
to induce any luciferase activity in our cells (data not shown) as they did not induce 
cell proliferation in the T-screen (Schriks et al., 2006) nor displace thyroid hormones 
from their transport proteins with high affinity (Lans et al., 1993; Marchesini et al., 
2008; Meerts et al., 2000). The presence of a hydroxyl group preferably adjacent to one 
halogen seems to be required to confer the thyroid hormone receptor binding affinity. 
One study has reported PCB inducible P4501A1 activity for their clone of GH3 cells 
(Gauger et al, 2007). This would be very relevant as the metabolism of PCBs and other 
compounds to hydroxylated metabolites occurs in vivo. However, the wild type GH3 
cells used to clone the new stably transfected GH3.TRE-Luc cell line do not show 
cytochrome P4501A activity in our hands and before (Gutleb et al., 2005; Schriks et al., 
2006). P4501A1 transcripts were also not detected by microarray analysis (data not 
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shown). An option to test non-hydroxylated compounds of interest is by pre-
incubation with microsomes to allow metabolism before exposure. It needs to be 
studied, however, to what extent the OH-metabolites can reach the same intracellular 
levels as the more lipophilic parent compounds (Schriks et al., 2006). Either reduced 
uptake or phase II metabolism may play a role. Also the relatively low induction of 
the reporter gene with the very T3-like OH-metabolites in our study suggest that the 
availability of the OH-metabolites might be the limiting factor in an in vitro cell 
system in contrast to in vitro binding assays. Therefore, we are currently performing 
subsequent experiments, which will allow these chemicals to be intracellularly 
hydroxylated. 
Our results also indicate that BPA (Figure 8), and its halogenated derivatives TBBPA 
and TCBPA may have the same mechanism of action as amiodarone in the GH3 cells. 
Up to a concentration of 1 $M they act as weak agonists (max. 5% effect), but above 5 
$M an antagonistic effect was observed (respectively Figure 9A and 9B). These very 
weak results suggest that the low dose response is not receptor-mediated, and with 
increasing concentration towards the receptor binding constant (Ki), binding may 
occur resulting in a tissue specific antagonist effect overriding the weak agonist effect. 
Previous studies have also reported that estrogenic chemicals may induce pituitary 
cell growth, however no estrogen-responsive proliferation was observed (data not 
shown) with this particular strain. A closer look into previous reports reveals that 
BPA induces cell proliferation alone and in combination with T3 in the T-screen 
performed with 10% dextran-charcoal treated FCS (Ghisari and Bonefeld-Jorgensen, 
2005). In a similar study with serum free medium only potentiation occurs (Schriks et 
al., 2006). It cannot be excluded that in the 10% DCC treated serum some hormones 
were still present as opposed to our serum free system. For BPA and its relatives, a 
multitude of contradicting effects in different reporter gene cells lines with different 
exposure conditions have also been reported (Moriyama et al., 2002; Kitamura et al., 
2005b; Yamada-Okabe et al., 2004), of which some are in agreement with recent in vivo 
studies (Heimeier et al., 2009). Therefore experimental dissimilarities, such as 
exposure concentrations and conditions as well as cellular contexts should be taken 
into account when trying to explain different effects of the same compound in 
different assays. 
Chapter 2 
 52 
In conclusion, the results of this study present the GH3.TRE-Luc assay as a promising 
tool to identify and quantify the thyroid receptor-mediated mechanism of action of 
compounds to which humans, animals and environment are regularly exposed. The 
assay is sensitive and versatile enough to screen for chemicals that are able to promote 
agonistic, antagonistic and potentiating thyroid receptor-mediated effects, very much 
like the T-screen. However, coupling the viable cell number end-point with the 
thyroid receptor-mediated luciferase activity, a distinction can be made between TR-
mediated and other mechanisms of action that induce cell proliferation. Also putative 
antagonists, in the T-screen, revealed to be merely reducing cell viability. In addition, 
indications for compounds with other possible modes of action were found for a 
variety of different chemical classes of environmentally relevant compounds. The 
modes of action of these compounds should be further studied.
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ABSTRACT 
 
o validate the use of the recently developed GH3.TRE-Luc cells for quantitative 
high-throughput screening, the GH3.TRE-luc assay was miniaturized and 
validated in a 1536-well plate format. The Library of Pharmacologically Active 
Compounds (LOPAC) and the National Toxicology Program (NTP) collection were 
screened for thyroid hormone receptor agonists and antagonists. Of the 2688 
compounds tested 8 or 1 were agonists depending on the positive hit cut-off defined 
at ≥10% or ≥20% efficacy, respectively and 5 were identified as antagonists. None of 
the inactive compounds were structurally related to thyroid hormones, nor reported 
to be thyroid hormone receptor disruptors, so false negatives were not detected. None 
of the low potency agonists structurally resemble thyroid hormones, thus these may 
not be active directly through the ligand-binding domain of the receptor and may not 
represent effective agonists. Defining agonists in the qHTS as requiring a hit cut off of 
≥20% efficacy at 100 "M may avoid identification of positives without physiological 
relevance. It is concluded that the miniaturized GH3.TRE-Luc assay offers a 
promising addition to the in vitro test battery for endocrine disruption, and that, given 
the low percentage of compounds testing positive, its high-throughput nature is an 
important advantage for future toxicological screening. 
T 
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INTRODUCTION 
 
he thyroid hormone (TH) system of vertebrates consists of an elaborate 
signaling network controlling critical processes throughout different life-stages 
such as regulation of energy metabolism (Cheng et al., 2010), growth and 
differentiation, development and maintenance of brain function (Horn and Heuer, 
2010; Warner and Mittag, 2012), thermo-regulation (Ribeiro, 2008), osmo-regulation 
and renal function (Vargas et al., 2006), regulating onset and proper function of other 
endocrine systems, sexual behaviour and fertility, cardiovascular functioning (Danzi 
and Klein, 2012). The possibility of alterations to the TH system by natural or 
synthetic compounds present in our food or the environment could therefore have 
substantial implications. In this context, the demonstration that certain manufactured 
chemicals exhibit thyroid-like activity (Gray et al., 1993; Porterfield and Hendry, 1998) 
generated an interest in the TH system due to its crucial role in growth, development 
and energy homeostasis (Silva, 2001; Yen, 2001). The TH signaling network relies on 
efficient and accurate interpretation of chemical signals by the thyroid receptors (TRs). 
Thyroid active compounds may interact at the level of these TRs but may also 
generate effects at several other targets in normal thyroid functioning. These include 
TH transport by transthyretin (TTR) or thyroxine-binding globulin (TBG) (Lans et al., 
1993); hormone production which essentially depends on iodine uptake (Hornung et 
al., 2010) and the enzyme thyroid peroxidase or thyroperoxidase (TPO) that 
incorporates iodine onto tyrosines from thyroglobulin for the production of thyroid 
hormones (Biegel et al., 1995); hormone activation or deactivation by iodothyronine 
deiodinases types I, II, and III (D1, D2, and D3, respectively) which regulate the 
activity of thyroid hormones via removal of specific iodine substituents, UDP 
glucuronosyltransferases (UGTs) or sulfotransferases (SULTs) which conjugate the 
thyroid hormones and facilitate their excretion from the body (Visser et al., 1979; 
Schuur et al., 1998); or transport of thyroid hormones over the membrane into the cell 
(Guo et al., 2002). Although for most of these targets an in vitro assay has already been 
developed (Murk et al., 2012), current risk assessment strategies still rely heavily on 
chemical safety data obtained in animal models. This low-throughput approach is 
relatively expensive and sometimes provides an unreliable representation of human 
T 
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toxicity. Furthermore, the use of large number of animals for toxicity testing raises 
legal and ethical considerations. The development of integrated and intelligent testing 
strategies for toxicity evaluation, such as innovative in vitro and in silico approaches 
have paved the way for the reduction of these vertebrate studies. The regulatory 
system for chemicals controlled by the European Chemical Agency (ECHA), called 
Registration, Evaluation and Authorization of Chemicals (REACH) placed a premium 
on functional quantitative high-throughput in vitro screening assays (qHTS) for the 
toxicological evaluation of the extraordinarily high number of natural and synthetic 
chemicals to be assessed within a few years (about 30,000 substances are currently 
marketed at volumes greater than 1 ton/year). A collaboration known as Tox21, 
comprised of the United States Environmental Protection Agency (US EPA), the US 
National Institutes of Health (NIH), and the US Food and Drug Regulatory Agency 
(FDA), has initiated a program of screening a large chemical library composed of 
environmental chemicals and pharmaceuticals through different qHTS assays 
developed based on specific biological mechanisms relevant to toxicity (Kavlock et al., 
2009; Shukla et al., 2010; Huang et al., 2011). These screening assays directly study the 
effects of thousands of potentially harmful chemicals on particular cellular systems or 
molecular targets. However, for TR-mediated disruption a functional qHTS assay 
based on endogenous full-length receptors is still lacking. Recently, we have 
developed and validated a stably transfected reporter gene cellular model based on 
the TH responsive rat pituitary tumor GH3 cell line that constitutively expresses both 
TR isoforms with TR# being predominant. Here, we present the development and 
application of the GH3.TRE-luc cell line using a qHTS system to test chemicals for TR 
activity with potential for endocrine disruption. This includes the miniaturization and 
optimization of the GH3.TRE-Luc assay into a 1536-wells plate format for agonistic, 
antagonistic and cytotoxic activities of the compounds tested. The qHTS system 
obtained was subsequently used to test the 1280 compounds of the LOPAC library 
(Library of Pharmacologically Active Compounds) (Xia et al., 2011a) and the 1408 
chemicals from the National Toxicology Program collection (NTP) (Xia et al., 2008). 
Intracellular ATP content was measured to ascertain that effects observed were not 
due to cytotoxicity. The chemical collections are used for validation of the high-
throughput screen (qHTS) because of their diverse chemical families, some proven to 
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be pharmacologically active, with almost all compounds previously tested in one or 
more standard toxicological assays. The outcomes of this preliminary screen were 
further examined to identify potential false positives and false negatives using the 
publically available PubChem Bioassay database. 
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MATERIALS AND METHODS 
 
Cell line and culture conditions. The GH3.TRE-Luc cell line developed as described 
(Freitas et al., 2011), stably expresses a modified firefly luciferase reporter gene under 
the regulation of a thyroid hormone response element (TRE). Cells were routinely 
sub-cultured once a week in fresh 75 cm2 culture flasks (Corning, Acton, MA), in a 
humid atmosphere at 37°C and 95% air/5% CO2 in Dulbecco’s Modified Eagle’s 
medium/Ham’s F12 (DMEM:F12, Invitrogen, Carlsbad, CA) supplemented with 10% 
Fetal Bovine Serum (FBS, Hyclone, Logan, UT). 
 
qHTS TRE luciferase reporter gene assay. For the TRE luciferase reporter gene assay 
GH3.TRE-Luc cells were seeded at 80% confluency in 225 cm2 culture flasks (Corning, 
Acton, MA) in regular growth medium and cultured overnight. Growth medium was 
then replaced by assay medium (Sirbasku et al., 1991) (DMEM:F12 supplemented 
with 10 µg/ml insulin, 10 µM ethanolamine, 10 ng/ml sodium selenite, 10 µg/ml 
human apotransferrin and 500 µg/ml bovine serum albumin) followed by a 20 hours 
incubation. Subsequently, cells were detached, re-suspended in assay medium and 
seeded at 1500 cells/well in 1536-well assay plates. For agonist mode screening cells 
were plated in 5 µl of assay medium. After culturing for 4-5 hours, 23 nl of required 
concentrations of test compounds or DMSO control were transferred using a Pintool 
(Wako, San Diego, CA) into each well resulting in a final DMSO concentration of 
0.46%. For antagonist mode screening, cells were plated in 4 µl, test compounds were 
added as indicated above and 1 µl of 1 nM final concentration T3 or assay media 
control was dispensed to each well. Plates were incubated with compound treatment 
for 24 hours. After this incubation, 5 µl of One-Glo luciferase reagent (Promega, 
Madison, WI) was added and plates were incubated at room temperature for 30 
minutes before reading on a Viewlux plate reader (PerkinElmer, Waltham, MA). 
The 1280 compounds from the Library of Pharmacologically Active Compounds 
(LOPAC, Sigma, St. Louis, Missouri, USA) (Xia et al., 2011a) and the 1408 chemicals 
from the National Toxicology Program collection (NTP) (Xia et al., 2008) were tested 
in series of 7 to 15 dilutions with final concentrations ranging from 0.6 nM to 92 µM 
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and 3 nM to 46 µM for the NTP and LOPAC collections respectively. The highest 
concentrations tested were judged to be at the very upper range of potential 
environmental exposures. The four left columns in each plate were reserved for 
controls. The control format for the agonist mode plate was column-1 T3 from 0.3 pM 
to 4.6 µM, column-2 T3 100 nM and column-3 to 4 DMSO only. The control format for 
the antagonist mode plate was column-1 to 2 DMSO only, column-3 to 48 T3 1 nM. In 
order to exclude the compounds that inhibit TR-induced luciferase reporter gene 
expression due to cytotoxicity, the LOPAC and NTP libraries were also tested for cell 
viability by measuring intracellular ATP content using a luciferase-coupled ATP 
quantitation assay (CellTiter-Glo viability assay, Promega, Madison, Wisconsin, USA). 
The cells were dispensed in 5 µl at 1500 cells/well in 1536-well white/solid bottom 
assay plates (Greiner, Monroe, NC) and the assay was run identically to the 
antagonist screen method mentioned above, with addition of 5 µl/well of CellTiter-
Glo reagent in place of One-Glo. After 30 minutes incubation at room temperature, the 
luminescence intensity was measured using a ViewLux plate reader (PerkinElmer). 
 
Data analysis. The primary data analysis was performed as previously described (Xia 
et al., 2011b). Briefly, raw plate reads for each titration point were first normalized 
relative to the T3 control (100 nM T3, set at 100% for agonist mode; 1 nM T3, set at 100% 
for antagonist mode) and DMSO only wells (basal, set at 0%), and then corrected by 
applying a pattern correction algorithm using compound-free control plates (DMSO 
plates) (Xia et al., 2011b). 
Concentration-response titration points for each compound were fitted to the Hill 
equation yielding concentrations for half-maximal activity for agonists (EC50) or half-
maximal inhibition for antagonists (IC50) and maximal response (efficacy) values. The 
concentration response curves of the compounds were classified into four major 
classes (1-4) based on the completeness of curve, goodness of fit, and efficacy (Xia et 
al., 2011b). Antagonists were identified using the selection criterion that their IC50 
values should be at least three times lower than the IC50 in the viability assay to 
exclude cases of cytotoxicity.
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RESULTS 
 
Assay optimization and miniaturization in the 1536-well plate format. The 
GH3.TRE-luc assay was initially miniaturized in a 1536-well plate with a 5 µl final 
assay volume. To find optimal cell density in the well, three different cell numbers 
were tested after treatment with various concentrations of the known agonist T3 
ranging from 0.3 pM to 4.6 µM for 24 hours. The EC50 values of T3 obtained amounted 
to 0.33, 0.55, and 0.39 nM at cell densities of 1000, 1500, and 2000 cells/well 
respectively (Table 1). The signal-to-background ratio (S/B) for these three cell 
densities was 7 to 9.5 fold. Z’ factor value from the density of 1500 cells/well was 0.88, 
which was the highest compared to other cell densities (1000 or 2000 cells/well). 
Therefore 1500 cells/well was chosen for use in the subsequent studies. 
 
Table 1. Assay optimization in 1536-well format. Cells were plated 4 hours prior to assay and stimulated 
with T3. Signal-to-background ratio (S/B) was calculated comparing the response of 4.6 "M T3 to DMSO 
controls. EC50 values were calculated from full dose response curves (n=3). Z’ factor was calculated using T3 
EC100 (n=3). 
 
Cells/well (5µl) S/B EC50 (nM) Z’ factor 
1,000 9.18 0.33 ± 0.032 0.76 
1,500 7.13 0.55 ± 0.036 0.88 
2,000 9.49 0.39 ± 0.038 0.76 
 
Further studies were conducted to optimize conditions to screen for thyroid receptor 
antagonist activity. Antagonist action can be identified based on the ability of the 
compound tested to block the effect of a sub-maximal concentration of the agonist T3. 
In order to determine the concentration of T3 to be used for qHTS determination of 
antagonist activity, two concentrations slightly above the EC50 of T3 (Table 2) were 
tested. At both T3 concentrations the assay shows a similar S/B ratio (3.6 and 3.7 fold) 
but the 1 nM T3 group gave a minimal CV (coefficient of variation, 7%) compared to 
the 0.5 nM T3 group (CV, 11%). Z’ factors (Zhang et al., 1999) were 0.44 and 0.65 for 
the 0.5 nM and 1 nM T3 exposure groups, indicating that 1 nM was a better 
concentration for screening for antagonist activity. This concentration represents one 
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that optimizes a large screening window without significant loss of sensitivity to 
detecting antagonists due to receptor binding competition with the T3 used in this 
assay mode. All further inhibition (antagonism) assays were run using 1 nM of T3 as 
the agonist. 
 
Table 2. T3 concentration optimization for antagonist mode screening in 1536-well format. Cells were plated 
4 hours prior to assay and stimulated with T3. Signal-to-background ratio (S/B) was calculated comparing 
the response of the respective T3 concentrations to DMSO controls. Coefficient of variation (CV) and Z’ 
factor were calculated using the indicated T3 concentrations (n=2). 
 
T3 (nM) S/B CV (%) Z’ factor 
0.5 3.6 11.1 0.44 
1 3.7 7.0 0.65 
 
Identification of TR agonists by qHTS. The qHTS GH3.TRE-luc assay was used to 
screen the LOPAC and NTP libraries for TR agonists and antagonists to provide a 
proof of principle for use of the newly developed biomolecular screening tool. For 
agonist screening, the concentration titration of T3, used as a positive control, was 
performed in each plate. The control dose-response curves of T3 were well reproduced 
in all 27 plates used for the screening of the two libraries, including 6 DMSO plates, 
with an EC50 average of 0.66 ± 0.13 nM (Figure 1). T3 controls averaged a signal-to- 
background ratio of 6.88 and 7.42 and the average Z’ factor was 0.82 and 0.77 in the 
LOPAC and NTP libraries screen, respectively (Table 3). 
Of the 1280 compounds from the LOPAC library, 6 (0.5%) were identified as potential 
TR agonists (Figure 2), with the positive hit cut off being compounds that gave a ≥10% 
efficacy. The potency and efficacy of these compounds are listed in Table 4. 
 
Table 3. Screening statistics for LOPAC and NTP libraries. Coefficient of variation (CV) calculated from 
control and low concentration plates. Signal-to-background ratio (S/B) and Z’ factor for agonist and 
antagonist mode determined for 100 nM T3 and 1 nM T3, respectively. 
 
 Agonist Mode Antagonist Mode 
Library CV (%) S/B Z’ factor CV (%) S/B Z’ factor 
NTP 9.21 ± 1.81 7.42 ± 0.51 0.77 ± 0.05 7.25 ± 3.77 4.71 ± 0.29 0.65 ± 0.08 
LOPAC 11.04 ± 1.99 6.88 ± 0.54 0.82 ± 0.05 7.83 ± 1.27 3.37 ± 0.18 0.76 ± 0.04 
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Figure 1. The intra-plate T3 dose-response curves for 27 different plates. In each plate T3 was used as 
positive control. After plated at 1500 cells/well in 1536-well plates and incubated for 4 hours, cells were 
stimulated with the indicated concentration of T3 for 24 hours. 
 
Table 4. Potency and efficacy for compounds identified in the LOPAC library screening. Potency (EC50 and 
IC50) values were calculated from full dose response curves in the absence and presence of T3 (1 nM), 
respectively. Efficacy was defined as percentage of maximal induction (agonist mode) or inhibition 
(antagonist mode) relative to T3 set at 100% (100 nM for testing of agonist and 1 nM for antagonist activity). 
Re-screen values listed in parenthesis. 
 
Agonists Potency, µM (re-screen) Efficacy, % (re-screen) 
retinoic acid 0.8 22.2 
CGP-7930 2.7 (2.6) 18.2 (18.0) 
CGP-13501 2.8 (2.3) 16.8 (15.0) 
13-cis-retinoic acid 6.4 (2.9) 18.8 (15.5) 
SKF-89145 hydrobromide 21.9 (20.6) 10.9 (16.5) 
4-hydroxybenzhydrazide 24.6 (26.0) 11.5 (17.5) 
Antagonists   
Tranilast 0.7 (0.8) -86 (81.8) 
SB 205384 2.6 (2.5) -75 (73.0) 
NS-1619 5.2 (13.4) -58 (75.7) 
5-fluorouracil 5.2 (3.1) -72 (71.1) 
 
Of the 1408 compounds from the NTP library, 2 (0.1%) were identified as potential TR 
agonists, with the positive hit cut off being compounds that gave a ≥10% efficacy. The 
potency and affinity of these compounds are listed in Table 5. 
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Figure 2. Examples of dose response curves in the qHTS for agonists identified in the LOPAC and NTP 
libraries screening. GH3.TRE-Luc induction after exposure to A) retinoic acid, B) CGP-7930, C) CGP-13501, 
D) 13-cis-retinoic acid, E) SKF-89145 hydrobromide, F) 4-hydroxybenzhydrazide, G) 13-cis-retinal, H) trans-
retinal. Luciferase activity (l, left axis) as relative percentage of T3 control (at 100 nM set at 100%, DMSO set 
at 0%) and the number of viable cells (○, right axis) expressed as relative percentage of DMSO control. 
Chemicals were tested in series of 7 to 15 dilutions with final concentrations ranging from 0.6 nM to 92 µM 
and 3 nM to 46 µM for the NTP and LOPAC collections respectively. 
 
In order to evaluate the reproducibility of the hits and validate the screen in qHTS 
format, the LOPAC library was re-screened three times. All 6 compounds identified 
from the primary screen showed similar activity in the re-screen (Table 4). When, for 
defining TR agonist activity, the positive hit cut off was set at ≥20% efficacy, only one 
TR agonist was identified in the LOPAC library and none in the NTP library. Close 
evaluation of the dose response curves obtained for the compounds that did not 
induce ≥20% efficacy, revealed that at the highest dose levels tested, 46 or 92 µM, 
maximum activity of some of the possible agonists may not yet have been reached. 
However, given that the highest concentrations tested were judged to be at the upper 
range of what would be relevant possible exposure levels, this supports the 
conclusion that they may not represent effective TR agonists. Furthermore, none of 
these compounds has structural characteristics that resemble the thyroid hormones T3 
and T4 (Figure 3), providing further support for the conclusion that they may not 
represent effective TR agonists. 
 
Table 5. Potency and efficacy for compounds identified in the NTP library screening. Potency (EC50 and 
IC50) values were calculated from full dose response curves in the absence and presence of T3 (1 nM), 
respectively. Efficacy was defined as percentage of maximal induction (agonist mode) or inhibition 
(antagonist mode) relative to T3 set at 100% (100 nM for testing of agonist and 1 nM for antagonist activity). 
 
Agonists Potency, µM Efficacy, % 
13-cis-retinal 7.1 11.8 
trans-retinal 14.9 11.4 
Antagonists   
5-fluorouracil 6.7 -86.7 
1-acetyl-2-phenylhydrazine 10.6 -87.5 
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Figure 3. Chemical structures of compounds tested positive for TR agonist activity. A) triiodothyronine (T3), 
B) thyroxine (T4), C) retinoic acid, D) 13-cis-retinoic acid, E) trans-retinal, F) 13-cis-retinal, G) CGP-7930, H) 
CGP-13501, I) SKF-89145 hydrobromide, J) 4-hydroxybenzhydrazide, K) Tranilast, L) NS-1619, M) SB 
205384, N) 5-fluorouracil and O) 1-acetyl-2-phenylhydrazine. 
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Identification of TR antagonists by qHTS. To identify the potential TR antagonists by 
using this GH3.TRE-luc assay, the LOPAC and NTP libraries were screened. In the 
antagonist mode screening, cells were exposed to the test compounds in the presence 
of 1 nM T3 and the ability of the compounds to inhibit T3-mediated TR activation was 
measured. The average signal-to-background ratio was 3.37 and 4.71, and the average 
Z’ factor was 0.76 and 0.65 for the LOPAC and NTP libraries, respectively. To 
ascertain that the inhibitory effect of the potential hits was not due to cytotoxic effects, 
a cell viability screen was performed in parallel. From the LOPAC screen, 4 
compounds (0.3%) were identified with an IC50 that was 3-fold lower than their 
viability IC50. The potency and efficacy of these compounds are listed in Table 4 and 
graphs given in Figure 4. From the NTP library, 2 compounds (0.1%) were identified 
with an IC50 that was 3-fold lower than their corresponding viability IC50. The potency 
and efficacy of these compounds are listed in Table 5 and graphs given in Figure 4. In 
order to evaluate the reproducibility of the hits and to validate the screen in qHTS 
format, the LOPAC library was also screened three times. All 4 compounds were 
confirmed in the re-screening. 
Altogether the data presented indicate reproducibility and provide a first proof of 
principle that the novel and robust GH3.TRE-luc assay can be utilized to screen large 
compound libraries in 1536-well plate format for TR agonist as well as antagonist 
activity. 
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Figure 4. Examples of dose response curves in the qHTS for antagonists identified in the LOPAC and NTP 
libraries screening. GH3.TRE-Luc induction after exposure, in the presence of 1 nM of T3, to A) Tranilast, B) 
SB 205384, C) NS-1619, D) 5-fluorouracil, E) 1-acetyl-2-phenylhydrazine. Luciferase activity (l, left axis) as 
relative percentage of T3 control (at 1 nM set at 100%, DMSO set at 0%) and the number of viable cells (○, 
right axis) expressed as relative percentage of DMSO control. Chemicals were tested in series of 7 to 15 
dilutions with final concentrations ranging from 0.6 nM to 92 µM and 3 nM to 46 µM for the NTP and 
LOPAC collections respectively. 
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DISCUSSION 
 
n the present study a quantitative high-throughput screen (qHTS) for TR agonist 
and antagonist activity was developed based on the recently developed in vitro 
reporter gene assay using the stably transfected GH3.TRE-Luc cell line (Freitas et al., 
2011). The assay was miniaturized and validated in a 1536-well plate format. 
Subsequently the 1280 compounds of the LOPAC library (Library of Pharmaco-
logically Active Compounds) and the 1408 compounds of the NTP collection were 
tested for their TR agonist or antagonist activity. Of the 2688 compounds tested in the 
qHTS 8 (0.3%) or 1 (0.04%) were found to be TR agonists depending on whether the 
positive hit cut off was defined at ≥10% or ≥20% efficacy. None of the inactive 
compounds were structurally related to T3, nor reported elsewhere to be thyroid 
hormone disruptors, so false negatives were not obvious in the screen. Furthermore, 
none of the low potency TR agonists has structural characteristics that resemble the 
thyroid hormones (Figure 3), providing further support for the conclusion that they 
may not represent effective TR agonists and may not activate the assay through 
binding to the TR ligand-binding domain. Defining TR agonists in the qHTS with a hit 
cut off of ≥20% efficacy at 100 "M may avoid identification of positives that are only 
very weak agonists and/or not acting through the ligand-binding domain. The 
GH3.TRE-Luc cells performed very well in an automated 1536-well plate format. The 
CV varied between 7-11% depending on the potency of the compounds tested, which 
is well within the performance standards for comparable assays in 1536-well plate 
format. 
The two chemical collections were used for validation of the high-throughput screen 
(HTS) because of their diverse chemical space, some proven to be pharmacologically 
active, with almost all compounds previously tested in one or more standard 
toxicological assays. They do, however, not specifically contain compounds known 
for their in vivo or in vitro thyroid hormone disrupting potency. For example, the 
known T3- and T4-like compounds such as Tetrac (3,5,3’,5’-tetraiodothyroacetic acid), 
Triac (3,5,3’-triiodothyroacetic acid) and OH-PHAHs (hydroxylated polyhalogenated 
aromatic hydrocarbons) such as TBBPA (4,4’-propane-2,2-diylbis(2,6-dibromophenol)) 
or OH-PCBs (hydroxylated polychlorinated biphenyls), PBDEs (polybrominated 
I 
Chapter 3 
 80 
diphenylethers) shown before to be active in the GH3.TRE-Luc assay (Freitas et al., 
2011) were not included. The LOPAC library contains pharmacologically active 
compounds, including many cytostatic compounds that could give growth inhibition 
hence reducing the luciferase activity. For compounds that do not directly antagonize 
the TR activity, the cell viability and the TRE-Luc inhibition IC50‘s will be similar. 
Therefore it is important to quantify the cell viability and calculate the ratio between 
the cell viability and the TRE-Luc inhibition IC50’s. When this ratio is less than 3, the 
compound is assumed to be merely cytotoxic instead of antagonistic. This approach 
has been used before for other reporter gene screens (Miller et al., 2010). One of the 
most potent TRE-Luc antagonists identified in the present screen was the anti-cancer 
drug 5-fluorouracil inducing a full dose-response curve without apparent cytotoxicity 
although it would be worthwhile to evaluate for cytotoxicity by alternative methods 
to provide higher confidence in interpretation of these results (Figure 4). It is of 
interest to note that one of the side effects of 5-fluorouracil is cardiotoxicity, the 
mechanism of which is still poorly understood (McGlinchey et al., 2001). Given 
however, that T3 is an important signaling molecules for cardiac function it seems 
worthwhile to study the possible role of the TR antagonism of 5-fluorouracil detected 
in the present study in the mode of action underlying this side effect. 
The most active agonists with EC50 values lower than 10 "M were the retinoids (13-
cis-retinoic acid and 13-cis-retinal) and the positive allosteric modulators of the GABA 
receptors GCP-7930 and GCP-13501 (Figure 2). The 13-cis-retinoids are known ligands 
of the TR heterodimer partner retinoid X receptor RXR (Li et al., 2002). RXR has been 
described both as a permissive heterodimer partner, i.e. activity at a thyroid receptor 
response element can be driven by RXR ligands, and as a non-permissive (Li et al., 
2002). It may be that the status of permissive versus non-permissive is defined by the 
specific cell system used for evaluation. In these rat pituitary GH3 cells, TR:RXR acts 
consistent with a permissive heterodimer. Interestingly, in another study 9-cis-retinoic 
acid significantly induced luciferase activity up to 20% of the T3-maximum response 
in the GH3.TRE-Luc cells but not in the TR$.HeLa-Luc cells (Freitas et al., 2012). The 
TR$.HeLa-Luc cells, with low expression levels of endogenous TRs, are stably 
transfected with TR$ and the same TRE-Luc construct as the GH3.TRE-Luc cells. The 
absence of luciferase induction in the TR$.HeLa-Luc cells by the retinoic acids suggest 
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that they also lack a functional RXR and this would corroborate the conclusion that 
the agonist activity detected in the GH3.TRE-luc cells may reflect RXR rather than 
direct TR agonist activity. This would also explain the retinoids antagonistic like 
behavior in the GH3.TRE-Luc assay without any structural resemblance to T3 or T4. It 
should be further studied whether a comparison between the TRE-Luc activation in 
the GH3.TRE-Luc and the TR$.Hela-Luc cells could be used to filter out RXR-active 
compounds, thereby reducing the chances on false positives in the GH3.TRE-Luc 
assay. 
The TRE-Luc potency of compounds that do not structurally resemble T3, is less than 
that of true TR-agonists such as the T3-like OH-BDE’s (Freitas et al., 2011). Therefore 
the cut-off of a maximum efficacy of ≥20% is also of use to filter out these compounds 
that are non-true TR-agonists. These less effective activators could be of interest as 
they may interact with pathways indirectly modulating TR activation, such as 
interactions with co-regulators or epigenetic modifications like effects on DNA 
methylation, chromatin structure or miRNA expression patterns. 
Taken together, the results obtained in the present study demonstrate the potential of 
the qHTS for the identification of novel thyromimetic compounds acting via a TR 
mediated mode of action. It is concluded that the miniaturized GH3.TRE-Luc assay 
offers a promising addition to the in vitro test battery for endocrine disruption, and 
that, given the low percentage of compounds testing positive, its high-throughput 
nature is an important advantage for future toxicological screening. 
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ABSTRACT 
 
H3 cells are highly responsive to thyroid hormone (TH) and are increasingly 
used in in vitro bioassays for TH disrupting chemical detection. These assays 
often rely on measurements of cell proliferation that may be subject to interference by 
compounds independently of their effects on TH signaling per se. Recently, we 
developed an integrated thyroid hormone response element (TRE) based luciferase 
reporter gene system using stably transfected GH3 cells (GH3.TRE-LUC) that offers a 
more specific means to detect compounds affecting thyroid hormone receptor (TR) 
activity. While these cells possess properties desirable for high-throughput screening 
approaches, altered reporter gene activity has not been compared to bona fide 
endogenous TH target gene expression changes. In this study, we treated GH3 cells 
with 3,3’,5-triiodothyronine (T3) as well as two TR isotype selective thyromimetics for 
either TR! or TR" (CO23 and GC-1, respectively). Response profiles in the TRE-based 
reporter gene assay showed excellent concordance with endogenous growth hormone 
(GH) gene expression, a known direct TH target gene. Further, we demonstrate that 
sodium arsenite, bisphenol A and the phthalate DEHP inhibit T3-mediated induction 
of the reporter gene as well as the endogenous GH gene. We then performed a 
microarray experiment to identify a fuller spectrum of T3 responsive genes in these 
cells, since promoter selective effects of synthetic nuclear receptor ligands may occur. 
In addition to identifying several important components of the TH signaling pathway, 
the microarray allowed us to identify a battery of both known and novel TH target 
genes, including genes related to angiogenesis such as HIF2! (EPAS1). Identification 
of these genes is important for validation of assays designed to identify new synthetic 
TR modulators and TR disrupting compounds, and their potential genomic versus 
nongenomic modes of action. 
G 
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INTRODUCTION 
 
hyroid hormones (TH), including the major product of the thyroid gland, 
thyroxine (T4), and the more active 3,3’,5-triiodothyronine (T3), are critical 
regulators of vertebrate development and metabolism. In humans, inadequate TH 
levels lead to moderate to severe mental retardation, ataxia, and sensory deficits along 
with delayed skeletal development and growth arrest (Williams, 2008). Even 
marginally low maternal thyroid function during pregnancy leads to significant 
decreases in mental capacity of the offspring. In adults, low TH levels lead to slowed 
basal metabolic rate and heart rate, as well as neurological issues such as attention 
deficit and depression-like symptoms. There is growing evidence that several 
environmental chemicals can negatively impact various aspects of the TH endocrine 
system, which has been the subject of several recent reviews (Diamanti-Kandarakis et 
al. 2009; Miller et al. 2009). Given the major role of TH in development, metabolic 
homeostasis, and reproduction, exposure to these chemicals could have adverse 
effects on human and animal health (Zoeller, 2007). In response to these concerns, the 
EPA incorporated animal based assays to detect potential thyroid hormone disrupting 
chemicals as part of the Tier 1 battery of the Endocrine Disruptor Screening Program 
(http://www.epa.gov/endo). While the prevailing notion to date has been that most 
TH disrupting chemicals act primarily to disturb TH synthesis or serum protein 
binding, recent evidence points to additional direct influences on the TRs themselves 
(Zoeller, 2005; Diamanti-Kandarakis et al. 2009). These effects may occur by directly 
binding to the receptors as agonists or antagonists, or indirectly by altering 
corepressor/coactivator recruitment and activity, for example. Furthermore, observed 
effects on the HPT axis could be mediated via the TRs, particularly by influencing 
negative feedback at the hypothalamus or pituitary via the TR" isotype. Therefore, it 
is of paramount importance to develop sensitive, reliable, and specific screening 
methods to detect TR mediated actions of chemicals, to include in a battery of in vitro 
methods with predictive value for the in vivo situation. Several cell-based methods for 
this purpose have been published (e.g. (Gauger et al. 2007; Hofmann et al. 2009; 
Shiizaki et al. 2010)), but suffer from various limitations such as low fold inductions, 
T 
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reliance on transient transfection methods, and/or the use of cells that are not 
normally TH responsive and with introduced TR over-expression may still lack 
important endogenous factors. 
The best understood actions of TH are mediated through a pair of thyroid hormone 
receptors, TR! or TR", and their splicing isoforms (Cheng et al. 2010). These highly 
conserved proteins are ligand-regulated transcription factors that bind near target 
genes via well-defined thyroid hormone response elements, and, on classically up-
regulated genes, repress or activate transcription in the absence and presence of 
hormone, respectively (Shi, 2009). TR! and TR" are expressed in tissue-specific 
manner and are believed to play both distinct and overlapping roles during 
development and in the control of metabolism (Flamant and Gauthier 2012). GH3 cells 
proliferate in response to T3 and T4, as well as environmental compounds such as 
hydroxylated metabolites of polybrominated diphenyl ethers (OH-PBDEs) (Schriks et 
al. 2006). However, the relative role of TR isotypes in GH3 cell proliferation is not 
known. Non-genomic actions of TH have also been proposed, acting via TRs outside 
the nucleus or via membrane receptors for TH or TH metabolites (Cheng et al. 2010). 
In particular, the nongenomic response has been linked to T4 induction of 
angiogenesis (Bergh et al. 2005). While the response to TH might be initiated at the 
membrane or in the cytoplasm, ultimately, downstream changes in gene expression 
could also occur. However, far less is known about the relative contribution of non-
genomic pathways in the myriad roles for TH in developing or adult organisms. 
A major unmet need in the study of TR disrupting chemicals has been the 
development of a sensitive and specific cell based assay, potentially amenable to high-
throughput screening. A rat somatotroph tumor-derived cell line GH3 that expresses 
all endogenous TR isoforms (Ball et al. 1997) and proliferates upon exposure to T3 or 
T3-like compounds (Schriks et al. 2006; Gutleb et al. 2005) was used to develop the 
stably transfected GH3.TRE-Luc reporter line (Freitas et al. 2011). The GH3.TRE-Luc 
line contains a stably integrated reporter construct containing two DR4 thyroid 
hormone response elements in tandem upstream of the SV40 small T antigen minimal 
promoter, driving a destabilized firefly luciferase cDNA (luc2CP). This luciferase 
reporter was chosen to reduce baseline expression yet retain high sensitivity. The T3 
responsiveness of the most inducible clone was optimized to twenty-four hour 
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exposure (prior to noticeable induction of proliferation) in serum free media. A cell 
viability assay conveniently quantifies metabolic activity of these cells prior to cell 
lysis for luciferase measurements, by monitoring conversion of resazurine to the 
fluorescent resorufin. Luciferase reporter activity was highly inducible and sensitive 
to low levels of T3, and there was a low coefficient of variation between assays (<5%) 
(Freitas et al. 2011). Furthermore, candidate environmental toxicants such as OH-
PBDEs and hydroxylated polychlorinated biphenyls (OH-PCBs) showed partial 
agonist activity and arsenic trioxide and BPA antagonized T3 induced reporter gene 
activity (Freitas et al. 2011), all consistent with previous findings in the literature. 
Despite these promising results, it is not yet known how well the integrated luciferase 
reporter gene serves as a surrogate for actual TH responsive target genes, a critical 
consideration should these cells be adopted by government, industry and academic 
scientists for TR disrupting compound screening. Furthermore, only a handful of 
endogenous TH responsive genes has been reported in GH3 cells despite the cell line’s 
long history in the field, including the discovery of the first TRE in the GH gene 
(Koenig et al. 1987). Therefore, determination of the genomic response to TH exposure 
in these cells will help reveal the mechanism of the proliferation response as well as a 
broader spectrum of TH target genes for post-screening validation. 
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MATERIALS AND METHODS 
 
Chemicals. All chemicals were of ≥98% purity unless stated otherwise. 3,3",5-Triiodo-
L-thyronine (T3, CAS no. 6893-02-3), 2,2-Bis(4-hydroxyphenyl)propane (BPA, CAS no. 
80-05-7), Bis(2-ethylhexyl) phthalate (DEHP, CAS no. 117-81-7), and sodium arsenite 
(CAS no. 7784-46-5) were purchased from Sigma-Aldrich Chemie B.V. (Zwijndrecht, 
Netherlands). 5-({4-[4-Hydroxy-3-(propan-2-yl)phenoxy]-3,5-diiodophenyl}methyl) 
imidazolidine-2,4-dione (CO23, CAS no. 911689-00-4) and 2-(4-{[4-hydroxy-3-(propan-
2-yl)phenyl]methyl}-3,5-dimethylphenoxy) acetic acid (GC-1, CAS no. 211110-63-3) 
were a gift from Thomas Scanlan (Oregon Health Sciences University, Portland, OR) 
and synthesized as described elsewhere (Chiellini et al. 2000; Ocasio and Scanlan 
2006).  All compounds were dissolved in dimethylsulfoxide (DMSO, 99.9%; Acros 
Organics, Geel, Belgium) and kept in the dark. Stocks were stored at −20°C until used. 
 
T-screen. The T-screen was carried out as previously described (Schriks et al. 2006). 
Briefly, GH3 cells were cultured in Dulbecco's modified eagle's medium/Ham's F12 
(DMEM:F12) with 15mM HEPES (Gibco) supplemented with 10% fetal calf serum 
(Gibco-Invitrogen). Cells were sub-cultured once a week in new 75cm2 culture flasks 
(Greiner). Forty-eight hours before T-screen, cells were incubated in a serum free 
medium (PCM medium (Sirbasku et al. 1991; Gutleb et al. 2005)) to deplete cells of 
thyroid hormones. Cells were then collected by scraping and seeded into transparent 
96-well plates (Greiner) at a density of 2500 cells/well. GH3 cells were exposed in 
triplicate and incubated for 96 h in the presence or absence of 0.25 nM T3, with or 
without the indicated test chemical (ranging from 0.1 $M to 10 $M) in DMSO (0.2%). 
A full T3 standard curve comprising a concentration range from 0 to 100 nM was 
included on each plate. Following the 96 h incubation, 8 $L of a 400 $M resazurine 
solution in PBS (Gibco) was added to each well. After 4 h incubation in the dark 
(37°C; 5% CO2) fluorescence was measured at %ex=530 nm and %em=590 nm on a 
Millipore Cytofluor 2350 Fluorescence Measurement System. 
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Reporter gene (luciferase) assay. The reporter gene (luciferase) assay was performed 
as described (Freitas et al. 2011). Briefly, GH3.TRE-Luc cells were seeded at 80% 
confluency in 75 cm2 culture flasks (Greiner) in DMEM:F12 with 15 mM HEPES 
(Gibco) supplemented with 10% fetal bovine serum (Gibco-Invitrogen) and 320 $g/ml 
of Geneticin (Gibco). Twenty-four hours later, growth medium was replaced by PCM 
medium for an additional period of 24 h. Cells were then collected by scraping and 
seeded into white clear bottom 96-well plates (Greiner) at a density of 3x104 cells/well 
and incubated for 24 h in the presence or absence of 0.25 nM T3, with or without the 
indicated test chemical in 0.2% DMSO. A full T3 standard curve comprising a 
concentration range from 0 to 100 nM, was included on each plate. Cell viability in 
each well was determined as described above and luciferase activity was measured in 
lysed cells in a microplate luminometer with two injectors (Thermo LabSystems 
luminoskan Ascent), as previously described (Murk et al. 1998). 
 
Microarray analysis. GH3 cells (ATCC CCL-82.1) were seeded in six well plates 
(Falcon) and grown to approximately 80% confluency in DMEM:F12 media with 10% 
fetal bovine serum (Invitrogen). Cells were then shifted to PCM medium for 48 hours, 
then treated in duplicate with 0.2% DMSO (vehicle), or 1 nM T3 (in an equivalent 
amount of DMSO) for 48 hours. Cells were harvested and total RNA prepared using 
an RNeasy kit (Qiagen). Integrity of the RNA was checked with an Agilent 
Bioanalyzer, and quantified with a Nanodrop ND-1000 spectrophotometer. 0.5 $g 
total RNA from each well was labeled with TotalPrep RNA Amplification Kit 
(Ambion), cRNA quality was verified with the BioAnalyzer, and found to have an 
average size of 1.2 kb. The biotinylated cRNA was used to probe an IIllumina RatRef-
12 Expression BeadChips (containing 22,523 probes representing 21,912 unique rat 
genes) at the UC Davis Genome Center gene expression core. Samples from two 
separate wells from each treatment group were used on the microarray. Illumina 
Beadstudio software was used to normalize the data. Genes with an average signal 
three times over background in at least one condition, and with an array detection p 
value < 0.01 were selected for further analysis. 
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Quantitative reverse transcriptase real time PCR (qPCR). GH3 cells were grown in 
six well plates in triplicate and treated as described for the microarray analysis. RNA 
was extracted as described in the previous section. cDNA synthesis of 1 $g total RNA 
was performed using the Quantitect Reverse Transcription kit (Qiagen). Quantitative 
real time PCR was performed using the SYBR green master mix (Applied Biosystems) 
in an Applied Biosystems 7900 HT FAST instrument at the Real-time PCR Research 
and Diagnostics Core Facility, School of Veterinary Medicine, UC Davis. Primers used 
were: Growth hormone forward 5’-CTCCCTGGCTCCTGACCTTC-3’, growth hormo-
ne reverse 5’-ATGTAGGCACGCTCGAACTCTT-3’; hairless forward 5’-CCTCCAG 
AGCGTTCGTATGAC-3’, hairless reverse 5’-GCTAAGCCCAACATCCCAGACT-3’; 
IGFBP3 forward 5’-GCGTGCAGAGCCAGTAGATACC-3’, IGFBP3 reverse 5’-TGTT 
GGCAGTCTTTTGTGCAA-3’; Aurora B Kinase forward 5’-AGAGCGGAACCTTCG 
ATGAG-3’, Aurora B kinase reverse 5’-CATCAGCGCGTCTGACAGTT-3’. Expression 
was normalized with the ribosomal L8 gene (rpl8), rpl8 forward 5’-TGCTAACCGAG 
CTGTTGTTGGT-3’, rpl8 reverse 5’- CAGCAGTTCCTCTTTGCCTTGT-3’.
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RESULTS 
 
Effects of T3, GC-1 and CO23 on GH3 cell proliferation. As shown in Figure 1, T3 
was the most potent in inducing proliferation, with an EC50 of 0.27 nM. Proliferation 
concentration-response curves for the relatively TR" selective ligand GC-1 and the 
relatively TR! selective ligand CO23, resulted in EC50‘s of 1.5 nM and 18 nM for GC-1 
and CO23, indicating they were approximately 5-fold and 67 times less potent than 
the T3 EC50, respectively. 
 
Figure 1. Effect of T3 and the isotype selective thyromimetics GC-1 and CO23 on GH3 cell proliferation.  
GH3 cells were treated for four days in serum free medium with the indicated concentrations of T3 (A), GC-
1 (B) or CO23 (C), and cell proliferation was measured using the conversion of resazurine to the fluorescent 
resorufin (RFU). 100% on y-axis represents the maximum T3 induced value. Bars represent the average 
value for each dose from 3-5 separate experiments, error bars represent SD. Representative graphs for each 
compound are shown here; a summary of the EC50 results averaged from these experiments is found in 
Table 1. 
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Figure 2. Concentration-dependent effect of T3 and the isotype selective thyromimetics GC-1 and CO23 on 
TRE based reporter gene and endogenous growth hormone gene expression in GH3 cells. GH3.TRE-LUC 
cells were treated with the indicated concentrations of T3 (A), GC-1 (C) or CO23 (E) and luciferase activity 
measured in cell extracts, normalized to resorufin formation. Parental GH3 cells were treated with the same 
concentrations of T3 (B), GC-1 (D), or CO23 (F) and analyzed for GH RNA expression by quantitative PCR, 
normalized to rpL8 expression. Error bars represent SD. *, p < 0.05 vs. untreated controls. 
 
Effects of T3, GC-1 and CO23 on a TRE-regulated reporter gene and endogenous 
growth hormone gene expression. Next, we used T3, GC-1 and CO23 in gene 
expression studies to provide a direct comparison to the T-screen results shown in 
Figure 1, and to uncover any potential isotype selectivity in target gene regulation in 
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GH3 cells. The response curves of the luciferase reporter in GH3.TRE-Luc cells were 
remarkably similar to the T-screen based proliferation results. GH expression in the 
parental GH3 cells in response to T3, GC-1 and CO23 (Figure 2) is somewhat more 
sensitive than the T-screen and reporter gene assays, but overall, the same pattern of 
relative potencies exists (T3>GC-1>>CO23). Thus, the proliferation and transcriptional 
responses to GC-1 (as measured by reporter gene activity and GH expression) are 
much closer to the natural ligand T3 than they are for CO23. The EC50 values for 
proliferation, reporter gene, and GH gene expression assays in response to T3, GC-1 
and CO23 are summarized in Table 1. 
 
Table 1. EC50 values of T3 and the thyromimetic compounds GC-1 and CO23 for proliferation, reporter 
gene, and endogenous gene regulation in GH3 cells. 
 
Compound T-screen EC50 (nM) 
T screen: 
% T3 max 
TRE-LUC 
EC50 (nM) 
TRE-LUC 
% T3 max 
GH qPCR 
EC50 (nM) 
GH qPCR 
% T3 max 
T3 0.27 100 0.3 100 0.2 100 
GC-1 1.5 82 1.1 108 0.5 117 
CO23 18 86 22 94 7.0 104 
 
The effect of putative environmental TR antagonists on reporter gene and GH 
gene expression in GH3 cells. In order to assess the reliability of the reporter gene 
assay to detect compounds that inhibit TR activity, we chose three environmentally 
relevant compounds previously linked to TH disruption: sodium arsenite (SA), 
bisphenol A (BPA), and di(2-ethylhexyl)phthalate (DEHP). SA and BPA have 
previously been shown to alter responses to TH in Xenopus laevis tadpoles and 
mammalian cells, but less is known about DEHP and TR activity. SA, BPA, and DEHP 
inhibited T3 induced luciferase activity as well as endogenous GH expression in a 
concentration-dependent manner (Figure 3). The effect of SA is biphasic on the GH 
gene, with significant induction at low doses and strong inhibition at the highest 
doses. On caveat of these findings is that the non T3 responsive gene used to 
normalize GH expression, rpl8, was also repressed at doses of SA>10 $M but to a 
lesser extent than GH expression was repressed, leading to the observed strong 
inhibition even upon normalization. SA did not affect viability as judged by the 
resazurine/resorufin assays, however. 
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Figure 3. Effect of selected endocrine disrupting chemicals on TRE based reporter gene and endogenous 
gene expression in GH3 cells. GH3.TRE-LUC cells were treated with DMSO (control), increasing 
concentrations of T3 (1, 10 and 100 nM), 1 nM T3 + increasing concentrations of sodium arsenite (C,D) (SA, 
0.1, 1, 10 and 100 &M), bisphenol A (E, F) (BPA, 0.1, 1, 10 and 100 &M) or Bis(2-ethylhexyl)phthalate (G,H) 
(DEHP, 1, 10, 100 and 1000 &M). In one set of cells (A, C, E, G), luciferase activity was measured in cell 
extracts, and normalized to resorufin formation. In a parallel set of cells, RNA was prepared for analysis of 
GH expression (B, D, F, H) by quantitative RT-PCR, normalized to rpL8 expression. Experiments were 
performed in triplicate; error bars represent SD. *, p < 0.05 vs. untreated controls (A, B), or versus 1 nM T3 
treated but compound untreated controls (C-H). 
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Identification of the T3 regulated transcriptome in GH3 cells. An important 
secondary screen of positive compounds following proliferation based assays in 
parental GH3 cells, or reporter gene based assays in GH3.TRE-Luc cells, will be to test 
positive “hits” for effects on endogenous TH responsive genes. We exploited an 
important advantage of using this normally TH responsive cell line to identify a 
signature of T3 genomic signaling for use in validation. Toward this end, we 
performed microarray analysis on the parental GH3 cells treated with 1 nM of T3 for 
48 hours. First, as shown in Table 2, the array results allowed us to examine the 
relative expression levels of multiple components of TR signaling in control and 
ligand treated GH3 cells. The array detected both TR isotypes, and both were 
modestly down-regulated by T3. The location of the probe in the TR" transcript, 
however, did not allow discrimination between TR"1 and TR"2. The TR heterodimer 
partners RXR" and (, but not !, were also detected. In addition, expression of the 
coactivator SRC-1 and the co-repressors NCoR and SMRT genes were detected, and 
SRC-1 is induced roughly two-fold by T3. The most abundant deiodinase detected in 
GH3 cells by the array was the Type I deiodinase (Dio1), and T3 induced the 
expression of this gene nearly 8 fold. Type II deiodinase expression was very low, but 
significantly expressed above background, whereas Type III deiodinase expression 
was not detected. Of several putative TH transporters included on the array, only the 
L-type amino acid transporter LAT1 and its heterodimer partner 4F2hc were 
significantly expressed, whereas other known transporters such as MCT8 and 
OATP1c1 were not detected. 
To determine a full set of genes differentially regulated by T3, we expanded our 
analysis of the array to focus on genes that were significantly expressed and changed 
at least 2-fold up or down compared to the vehicle treated control cells. We identified 
207 genes two-fold up-regulated and 312 genes two-fold down-regulated by T3, 
including several previously known TH response genes from other cell types and 
tissues including Dio1. Genes induced over four-fold are shown in Table 3.  
qPCR was used to validate expression of selected genes from the array, confirming 
the pattern and magnitude of up-regulation of the hairless and IGFBP3 genes, and 
down-regulation of the Aurora B kinase (AURKB) gene (Figure 4). 
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Table 2. Expression of selected thyroid hormone signaling pathway components in GH3 cells detected by 
Illumina microarray. 
 
Gene Definition Average signal, Control 
Average signal, 
T3 
 Nuclear receptors   
Thra Thyroid hormone receptor alpha 1356.8 1164.7 
Thrb Thyroid hormone receptor beta 2448.1 1562.9 
Rxra Retinoid-X receptor alpha ND ND 
Rxrb Retinoid-X receptor beta 1465.0 2028.9 
Rxrg Retinoid-X receptor gamma 245.2 203.7 
 Nuclear receptor coregulators   
Ncoa1 Nuclear receptor coactivator 1 (SRC-1) 2021.3 4243.0 
Ncoa2 Nuclear receptor coactivator 2 (SRC-2, Tif2) ND ND 
Ncoa3 Nuclear receptor coactivator 3 (SRC-3, ACTR) ND ND 
Ncor1 Nuclear receptor corepressor 1 (NCoR) 602.2 723.1 
Ncor2 Nuclear receptor corepressor 2 (SMRT) 527.0 655.8 
 Deiodinases   
Dio1 Deiodinase, Type I 238.2 1872.7 
Dio2 Deiodinase, Type II 56.3 65.4 
Dio3 Deiodinase, Type III ND ND 
 TH transporters   
SLC16A2 Solute carrier family 16, member 2 (MCT8) ND ND 
SLCO1C1 Solute carrier organic anion transporter family, 
member 1C1 (OATP1c1) ND ND 
SLC3A2 Solute carrier family 3, member 2 (4F2hc) 8997.8 7666.7 
SLC7A5 Solute carrier family 7, member 5 (LAT1) 2737.5 1606.2 
 Housekeeping genes   
Rpl8 Ribosomal protein L8 32692.9 34535.4 
Gapdh Glyceraldehyde 3-phosphate dehydrogenase 3580.6 3878.3 
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Table 3. List of genes up regulated over 4 fold by T3 in GH3 cells. 
 
Gene Definition T3 Fold change 
RGD1562107 PREDICTED:  similar to class-alpha glutathione S-transferase 37.5 
Es1 esterase 1 13.2 
LOC686871 PREDICTED:  similar to B-cell leukemia/lymphoma 3  (Bcl3) 11.8 
Slc14a1 solute carrier family 14 (urea transporter), member 1 10.2 
LOC681126 PREDICTED:  similar to keratin complex 2, basic, gene 25, transcript 
variant 1 9.2 
RGD1566155 PREDICTED:  similar to 2610030H06Rik protein 8.9 
Dio1 deiodinase, iodothyronine, type I 7.9 
Prm2 protamine 2 7.6 
LOC363618 PREDICTED:  similar to heparan sulfate (glucosamine) 3-O-
sulfotransferase 3A1 7.6 
RGD1562954 PREDICTED:  similar to aldo-keto reductase family 1, member C12 6.3 
Actn2 PREDICTED:  actinin alpha 2 5.8 
Shh sonic hedgehog 5.4 
Abcb1b ATP-binding cassette, sub-family B (MDR/TAP), member 1B 5.3 
LOC683720 PREDICTED:  similar to keratin 6L 5.3 
Epas1 endothelial PAS domain protein 1 5.2 
Pgf placental growth factor 5.1 
RGD1565373 PREDICTED:  similar to CD69 antigen (p60, early T-cell activation 
antigen) 4.8 
Hr hairless homolog 4.8 
Sfxn5 sideroflexin 5 4.6 
Irak2 interleukin-1 receptor-associated kinase 2 4.5 
Sstr2 somatostatin receptor 2 4.5 
Rims1 regulating synaptic membrane exocytosis 1 4.4 
Tnnc2 troponin C type 2 (fast) 4.3 
RGD1564287 PREDICTED:  similar to mKIAA0704 protein 4.3 
Bhlhb2 basic helix-loop-helix domain containing, class B2 4.2 
Igfbp3 insulin-like growth factor binding protein 3 4.1 
Lgals3 lectin, galactose binding, soluble 3 4.1 
Acta1 actin, alpha 1, skeletal muscle 4.1 
Epn3 epsin 3 4.0 
Bcar3 PREDICTED:  breast cancer anti-estrogen resistance 3 4.0 
Vdr vitamin D (1,25- dihydroxyvitamin D3) receptor 4.0 
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Figure 4. Validation of selected response gene expression changes from the microarray analysis by 
quantitative RT-PCR. Comparison of microarray derived gene expression changes (A, C, and E; black bars, 
value of one replicate; gray bars, value of second replicate) versus quantitative PCR derived gene 
expression changes (B, D, and F). Selected genes were hairless (Hr, A and B), insulin-like growth factor 
binding protein 3 (IGFBP3, C and D), and Aurora kinase B (E and F). Control and 1 nM T3 treated cells were 
used for qPCR (B, D, and F) and for microarray experiment (A, C, E). *, p < 0.05 vs. untreated controls. 
 
We then investigated whether there were enriched T3 regulated biological pathways 
in GH3 cells, using the web based DAVID program (Table 4). The most over-
represented pathways for T3 up-regulated genes cluster into two basic categories: 1) 
responses to extracellular (i.e. hormonal) signals, and 2) blood vessel development, or 
angiogenesis. The response to extracellular signals cluster includes several nuclear 
receptors, such as the estrogen receptor !, retinoic acid receptor !, and Vitamin D 
receptor genes, as well as the previously noted SRC-1 nuclear receptor coactivator 
genes. The blood vessel development cluster includes regulators of angiogenesis such 
as Endothelial PAS domain-containing protein 1 (Epas1), or HIF2!, placental growth 
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factor (Pgf), a member of the VEGF family, and angiopoietin 1 (Angpt1). 
Unexpectedly, the most over-represented pathways for T3 down-regulated genes were 
related to cell cycle control, including multiple cell division cycle genes (cdca1, cdca3, 
cdca7, cdc2, cdc6, cdc20, and cdc23) that are active at various stages of the cell cycle, 
multiple minichromosome complex maintenance genes (MCM2-7, MCM10) involved 
in origin of replication licensing at S phase, and Aurora kinase B (AURKB) involved in 
chromatin condensation at M phase. IGF-1 and associated IGFBPs have been 
previously shown to be up-regulated by T3 in other pituitary tumor cell lines, and are 
proposed to be mediators of the proliferative response of these cells to the hormone 
(Gilchrist et al. 1995). Indeed, IGFBP3 was up-regulated by 1 nM T3 (Table 3, Figure 
4C, D). To investigate the apparent paradox of induced proliferation in the face of 
repressed expression of cell cycle genes, we examined expression of IGF-1 (not 
represented on the array) and a marker of proliferation (AURKB) both at 24 hours 
prior to the time point chosen for the array, and at 96 hours, just prior to when 
proliferation was measured by the resazurine/resorufin assay. 
As shown in Figure 5, we found that IGF-1 is modestly induced 24 and 96 hours after 
exposure, consistent with previous reports, whereas AURKB is repressed 24 hours 
(and at 48 hours, see Figure 4) after exposure, but not 96 hours after exposure. This 
demonstrates that the early repressive effect of T3 on cell cycle gene transcription 
might be overcome by induced growth factor expression and return of cell cycle gene 
expression to baseline. 
 
Figure 5. T3 induces delayed IGF-1 expression while transiently suppressing Aurora B kinase expression in 
GH3 cells. GH3 cells were cultured in PCM media, then treated with DMSO or T3 for 24 or 72 hours. RNA 
was isolated for quantitative RT-PCR for the IGF-1 (black bars) or Aurora kinase B (gray bars) genes, 
normalized to rpL8 expression. Error bars represent SD. *, p < 0.05 vs. untreated controls. 
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Table 4. Top ranking Gene Ontology terms for T3 up- and down-regulated genes. 
 
Biological Process Term Count % P Value 
Up-regulated genes 
GO:0048545~response to steroid hormone stimulus 13 11.11 3.86E-06 
GO:0010033~response to organic substance 22 18.80 1.32E-05 
GO:0009719~response to endogenous stimulus 17 14.53 1.34E-05 
GO:0001944~vasculature development 11 9.40 2.14E-05 
GO:0009725~response to hormone stimulus 15 12.82 5.91E-05 
GO:0001525~angiogenesis 8 6.84 6.11E-05 
GO:0001568~blood vessel development 10 8.55 1.01E-04 
GO:0048514~blood vessel morphogenesis 9 7.69 1.30E-04 
GO:0007242~intracellular signaling cascade 20 17.09 1.35E-04 
GO:0001666~response to hypoxia 9 7.69 1.57E-04 
GO:0009991~response to extracellular stimulus 11 9.40 1.63E-04 
Down-regulated genes 
GO:0007049~cell cycle 28 18.42 3.36E-15 
GO:0022403~cell cycle phase 20 13.16 2.13E-13 
GO:0000279~M phase 18 11.84 2.29E-13 
GO:0000087~M phase of mitotic cell cycle 14 9.21 8.75E-12 
GO:0022402~cell cycle process 21 13.82 4.64E-11 
GO:0006260~DNA replication 14 9.21 8.27E-11 
GO:0007067~mitosis 13 8.55 9.49E-11 
GO:0000280~nuclear division 13 8.55 9.49E-11 
GO:0000278~mitotic cell cycle 17 11.18 1.56E-10 
GO:0048285~organelle fission 13 8.55 1.89E-10 
GO:0006259~DNA metabolic process 20 13.16 2.97E-10 
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DISCUSSION 
 
n this study, we demonstrate that the reporter gene assay developed in GH3.TRE-
LUC cells is an excellent surrogate for several specific endogenous gene responses 
to T3, isotype thyromimetic drugs, and environmental endocrine disrupting 
chemicals. The reporter assay provides greater speed and more specificity than the 
previously developed T-screen that relies on an indirect detection of cell proliferation. 
Since induction or inhibition of cell proliferation could occur via multiple pathways 
unrelated to the activity of the TRs, development of more specific assays for TR 
function, such as the reporter system described here that closely mimics endogenous 
gene behaviors, is highly desirable. In comparing the T-screen proliferation results to 
the reporter and endogenous gene (GH) assays, we found close concordance among 
the assays, including the same rank order of potency of T3 vs. two thyromimetic 
isotype selective compounds, GC-1 and CO23 (T3>GC-1>>CO-23). Thus, for these 
compounds, the reporter gene assay is highly predictive of both a phenotypic 
response (proliferation) and an endogenous gene response, but in a much more 
convenient format that is adaptable for high-throughput assay development. 
Additionally, our results with the isotype selective ligands suggest that the GH3 
cellular responses induced by T3 are predominantly TR" mediated, due to the strong 
selectivity of GC-1 for TR" over TR!. Additional experiments using both isotype and 
isoform selective siRNA knockdown approaches, for example, will be necessary to 
more fully address this issue. 
In addition to T3 and the selective thyromimetic agonists, reporter gene and 
endogenous gene responses were also similar for environmental TR antagonists, such 
as arsenic trioxide, BPA, and DEHP. In all three cases, T3 induced reporter gene and 
GH gene expression was inhibited in a concentration-dependent manner. Another 
direct target gene, hairless, also showed a similar pattern of responses (data not 
shown). The inhibition of T3 induced genomic responses in Xenopus laevis tadpole 
tissues reported previously for both arsenic and BPA (Heimeier and Shi 2010; Davey 
et al. 2008) is consistent with our results. One difference between the reporter gene 
and endogenous gene assays was that GH gene expression was induced at low 
I 
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concentrations of arsenic but repressed at higher concentrations. Modest induction of 
the Dio1 gene in GH3 cells by arsenic was previously reported (Davey et al. 2008). 
DEHP also inhibits T3 induced transcription in GH3 cells, an important observation 
given the ubiquitous presence of phthalates in the environment (Schettler, 2006) and 
consistent with other reports of links to potential TR disruption, including reporter 
gene assays (Shen et al. 2009; Sugiyama et al. 2005; Shi et al. 2012). Work on the 
endocrine disrupting activity of BPA and phthalates like DEHP have generally 
focused on ER rather than TR activity. Our results, as well as other in vitro and in vivo 
results, support further investigation into effects of phthalates on additional nuclear 
receptors, including the TRs. While the exact mechanisms underlying repression of T3 
induced transcription by compounds like arsenic, BPA, and DEHP is unknown at 
present, they may not necessarily involve direct interaction of the compounds with 
the TRs themselves. Rather, these and related compounds may affect TR mediated 
transcriptional control via interference with associated coactivator or corepressor 
interactions, post-translational modifications and/or activity, or indirectly via 
membrane TH transport or deiodinase activity. For example, arsenic has been shown 
to affect corepressor SMRT phosphorylation and nuclear translocation (Hong et al. 
2001). Since GH3 cells naturally respond to T3, these cells present a good in vitro 
model system to investigate the mode of action of these and other environmentally 
relevant chemicals affecting TH signaling. 
Given the importance of GH3 cells as an in vitro model for TR action, and their use as 
a screening system for TH disruption, a fuller understanding of the T3 induced gene 
expression responses in these cells is important. Further, while the GH gene has 
proven to be a useful marker of T3 action in these cells, other hormones and signaling 
cascades may influence GH expression as well; for example glucocorticoids, cAMP, 
and retinoids among others (Brent et al. 1988; Bedo et al. 1989). Therefore, we 
conducted a microarray analysis to delineate the T3 induced transcriptome in these 
cells. Our microarray analysis revealed a number of important characteristics 
regarding the responsiveness of these cells to T3. First, the array detected expression of 
both TR isotypes, and GH3 cells have been shown to express TR!1 and the non-ligand 
binding TR!2 splicing isoform, and two TR" splicing isoforms (TR"1 and TR"2) (Ball 
et al. 1997; Hahn et al. 1999; Lazar, 1990). In addition to the TRs, the array indicated 
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that these cells express two RXR isotypes (" and (), at least one nuclear receptor co-
activator which is T3 inducible (SRC-1), and two nuclear receptor co-repressors (NCoR 
and SMRT), again in agreement with previous published findings in GH3 cells (Misiti 
et al. 1998; Haugen et al. 1997; Davis and Lazar 1992). Type I deiodinase (Dio1) 
expression was both detected in controls and strongly induced by T3, with lower 
expression of the Type II deiodinase (Dio2). The T3 and T4-inactivating Type III 
deiodinase (Dio3) was not detected in these experiments, although a probe was 
included on the array. Expression of the TRs, RXRs, and associated coregulators, the 
low level of Dio3 expression, and abundant heterodimeric LAT1/4F2hc TH 
transporter expression, is consistent with the high sensitivity of these cells to T3. 
In terms of the T3 induced gene expression program in these cells, in general, up-
regulated genes mostly fell into two general categories: genes often induced by 
various extracellular signals, including hormones, and genes involved in angiogenesis 
or as a response to hypoxia. In the former group, there were several genes identified 
that have been identified as TH responsive genes in several different contexts; these 
genes may be considered a common “core” that when taken together, reflect the 
presence of T3 and a functional TR. For example, the aforementioned Dio1 gene 
(Zhang et al. 1998), the B-cell leukemia/lymphoma 3 (Bcl3) (Choi et al. 2008), sonic 
hedgehog (Shh) (Desouza et al. 2011), multidrug resistance (Abcb1b) (Kurose et al. 
2008), the corepressor hairless (hr) (Thompson and Bottcher 1997), and Klf9/BTEB 
(Denver and Williamson 2009) genes (Table 3, supplemental Table 1 can be found at 
https://dl.dropbox.com/u/1184226/GH3_array_1.5_fold_regulated_genes.xlsx) have 
all been identified as TH inducible in other cell types and contain functional TREs, 
adding additional confidence that the array detected bona fide T3 responsive genes. 
Interestingly, a large group of T3 up-regulated genes were linked to blood vessel 
formation and response to hypoxia. TH is a known inducer of angiogenesis in the 
mammalian heart and brain (Zhang et al. 2010) and the chick chorioallantoic 
membrane model (Mousa et al. 2005). Data from a recent series of papers support a 
non-genomic role for T4 (and, to a certain extent, T3) in the induction of angiogenesis 
and associated genes (reviewed in (Cheng et al. 2010; Moeller and Broecker-Preuss 
2011)). Tumor growth has also been linked to non-genomic actions of T4 (Mousa et al. 
2005). Essentially, two non-genomic pathways mediating TH signaling have been 
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proposed: first, integrin !v"3 binds to and is activated by T4 at the plasma membrane, 
and blockade of T4 binding by various means prevents downstream T4 induced 
angiogenesis. GC-1 is also able to induce angiogenesis via integrin !v"3 (Bergh et al. 
2005). Second, cytoplasmic, liganded TR"1 has been shown to interact with and 
activate PI3 kinase, inducing downstream pathways leading to HIF1! induction and 
subsequent activation of HIF1! targets, such as various glycolytic enzyme genes and 
angiogenic factors. With regards to TH signaling and gene expression in GH3 cells, as 
investigated here, there are several considerations relevant to understanding the 
underlying direct genomic versus nongenomic mechanisms at play. For example, 
tetraiodothyroacetic acid (Tetrac), another thyromimetic analog, acts as an antagonist 
at integrin !v"3 and inhibits T4 induced angiogenesis (Davis et al. 2009). However, 
Tetrac, like its related natural ligand T4, is a weak but full agonist in both the GH3 cell 
proliferation and GH3.TRE-LUC reporter gene assays (Schriks et al. 2006; Freitas et al. 
2011), indicating that these responses are mediated by classical genomic mechanisms 
via nuclear TR actions. Further, classical genomic pathways have been reported for T3 
induction of HIF1! in HepG2 cells, via prior induction of hepatic leukemia factor 
(HLF), a direct target gene of the TR (Otto and Fandrey 2008), although an HLF probe 
was not included on this array. In GH3 cells, HIF1! and several of its downstream 
targets (e.g. VEGFA, PFKP) are induced by T3 (~1.5 fold), but only modestly 
(supplemental Table 1), whereas HIF2! (EPAS1) is over five-fold induced (Table 3) 
and shares some overlapping gene targets with HIF1!. To our knowledge, this is the 
first report of HIF2! as a TH responsive gene, and it will be interesting to examine its 
mechanism of up-regulation. Future experiments will be important to clarify the 
mechanism of induced angiogenesis/hypoxia related gene expression in this system, 
including the relative role of classical genomic versus non-classical but receptor 
mediated (TR"/PI3K pathway) or integrin !v"3 mediated pathways. 
The analysis of the down-regulated gene program in GH3 cells presents somewhat of 
a paradox, certainly in explaining the proliferative response to T3 in these cells. Under 
our experimental conditions, a large number of cell cycle related genes are repressed, 
rather than induced, compared to vehicle control after 48 hours of exposure. In 
contrast, other studies using related pituitary tumor cell lines (GC cells, for example), 
reported increases in cyclin and cdk gene expression upon T3 treatment (Barrera-
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Hernandez et al. 1999). One explanation for our findings is that repression of cell cycle 
genes may be transient, and eventually overcome by secondary induction of various 
growth factors, including IGF-1. Consistent with other studies in related cells, we 
observed a T3 induced increase in both IGF-1 and IGFBP (IGFPB3) expression 
(Gilchrist et al. 1995) (Figure 4 and 5), although IGFBP3 has been reported to show 
both growth stimulatory and inhibitory properties (Jogie-Brahim et al. 2009). It is 
interesting to note that pituitary (thyrotrope) tumorigenesis is promoted in vivo by the 
expression of a dominant negative TR" protein (TRPV) that does not bind ligand, and 
that liganded wild type TR"1 represses cyclin D2 expression (Furumoto et al. 2005). 
Thus, in GH3 cells, the wild-type TR mediated response may be inhibition of 
proliferation-associated genes that is offset by autocrine growth factor expression, 
allowing a net stimulation of proliferation. Responses of cell cycle related genes might 
also be sensitive to other variables that differ between our conditions and those used 
in other studies, such as plating density and media formulations (Gilchrist et al. 1995; 
Barrera-Hernandez et al. 1999). 
In summary, we demonstrate good agreement between the T3 inducible reporter gene 
in GH3.TRE-LUC cells and endogenous gene responses, in response to thyromimetic 
agonists and environmental chemicals that antagonize TR activity. Further, our data 
support the conclusion that the proliferative response and the T3 induced 
transcriptional responses in GH3 cells appear to be largely TR" mediated. These 
findings help to validate the use of these cells for high-throughput screening for 
clinically relevant agonist and antagonists or environmental toxicants affecting TH 
signaling, particularly mediated by the TR" isotype. Recently a TR!-responsive 
reporter gene assay has been developed in HeLa cells, to be able to distinguish TR! 
and TR"-specific effects of compounds (Freitas et al., 2012). Lastly, GH3 cells may 
provide a good experimental system to investigate the relative importance of genomic 
and nongenomic pathways leading to transcriptional responses to TH, of relevance 
not only for understanding the role of TH in angiogenesis and tumor progression, but 
also for modes of endocrine disrupting chemicals affecting TH activity. 
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ABSTRACT 
 
hyroid hormone (TH) disrupting compounds can interfere with critical 
processes such as brain development, growth and energy homeostasis. THs act 
via thyroid receptors (TR) TR! and TR", which have distinct physiological functions, 
therefore it is important to study the TR-specific potency of TH active compounds. 
This study describes the development of TR! and TR" transient luciferase reporter 
gene bioassays using human cervical HeLa cells, in conjunction with the development 
of a stable TR! specific reporter gene cell line designated TR!.HeLa-Luc. Responses 
in this TR! cell line were compared to responses in the GH3.TRE-Luc cell line, which 
appears to contain TR" as the major TR isoform. The TR isoform-selective chemicals 
CO23 and GC-1 induced responses according to the anticipated rank order 
T3>CO23>GC-1 in the TR!.HeLa-Luc cells and T3>GC-1>CO23 in GH3.TRE-Luc cells. 
In addition to 7 known TR-active standards, 10 chemicals suspected to have TR 
disrupting activity were tested. Of these, only sodium arsenite and T3-like 4-OH-
BDE69 induced a response in the TR!.HeLa-Luc assay. Together, the developed and 
validated TR!.HeLa-Luc and GH3.TRE-Luc stable reporter gene lines add a new level 
of specificity, representing an improvement of the available tools for in vitro high-
throughput assessment of TR subtype-specific activity of drugs and environmental 
pollutants. 
T 
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INTRODUCTION 
 
he thyroid endocrine system is involved in a number of critical physiological 
processes that regulate brain development, growth and energy homeostasis 
(Bernal, 2007; Alkemade, 2010; Combs et al., 2011). The regulation of these processes is 
mediated by the thyroid hormones (THs) triiodothyronine (T3) and to a lesser extent 
thyroxine (T4), both small, lipophilic molecules built from tyrosine and iodine. The 
thyroid gland secretes mostly T4; T3 is produced from enzymatic deiodination of T4 in 
peripheral tissues and is considered to be the active hormone form due to its high 
binding affinity to the thyroid hormone receptors (TRs). It is generally accepted that 
deiodination of T4 is the major pathway through which T3 bioavailability is regulated 
in mammalian tissues (Köhrle, 2000). THs induce their physiological effects via the 
TRs (Samuels and Tsai, 1974), which belong to the large super family of nuclear 
hormone receptors including the steroid hormone, vitamin D and retinoic acid 
receptors (Beato et al., 1995). These receptors are ligand-dependent transcription 
factors able to interact with DNA sequences known as response elements, usually 
located in the vicinity of target genes (Desvergne, 1994). TRs are expressed in virtually 
all cells, and encoded by two different genes: TR! (NR1A1) and TR" (NR1A2), in 
humans on chromosomes 17 and 3 respectively. These two receptors differ in their 
relative and absolute tissue distribution, also depending on developmental stages 
(Bradley et al., 1989; Furlow and Neff, 2006), suggesting an important role for TR 
subtypes in mediating tissue specific responses to the hormone. Indeed, mouse 
knockout experiments have demonstrated both overlapping and distinct effects for 
each receptor isotype (Flamant and Samarut, 2003). In addition several isoforms of 
these receptors are generated through alternative splicing (Lazar, 1993). TR!1 is 
predominant in the central nervous system (CNS) and heart, and TR!2 is also 
expressed in the CNS but is unable to bind T3 and may exert a weak dominant 
negative effect on TR!1 and TR" isoforms (Katz and Lazar, 1993). TR"1 is most 
prevalent in the liver and kidney and TR"2 in the pituitary and hypothalamus (Yen, 
2001). Since T3 binding is nonselective towards any of the isoforms, an excess or 
shortage of THs may cause very different tissue-specific effects. For instance, the 
T 
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administration of T3 has a lowering effect on plasma cholesterol levels through TR"1 
activation (Pelletier et al., 2008), however cardiac side effects via the TR!1 such as 
tachycardia are sometimes difficult to avoid during TH replacement therapy. A TR"1 
selective agonist could be useful to treat chronic diseases such as obesity and 
hypercholesterolemia, avoiding therapeutic complications with cardiovascular or 
other predominantly TR!-regulated systems. As selectivity towards the ! or " 
subtypes remains a paramount criterium for the development of such chemicals (i.e. 
Selective thyroid hormone receptor modulators or STORMS) (Flamant and Samarut, 
2003), the possibility of a TR ligand with clinically useful properties makes these 
receptors very attractive targets for new drug development (Hirano and Kagechika, 
2010; Scanlan, 2010). 
In addition to clinical implications, understanding receptor isotype selectivity could 
also be important in determining and predicting the actions of endocrine disrupting 
chemicals. Xenobiotics defined as thyroid disrupting chemicals (TDCs) (Crofton, 2008) 
target the TH system by hampering the normal function of the thyroid gland 
(Hornung et al., 2010), interfering with enzymes linked with TH homeostasis (Barter 
and Klaassen, 1992), inhibiting plasma TH transport (Brouwer and van den Berg, 
1986), altering TH tissue concentrations (Gereben et al., 2008) and ultimately 
modulating TR-regulated genes (Bogazzi et al., 2003; Amano et al., 2010). Some of 
these chemicals may act as TH analogs (Zoeller, 2005), binding the TR and disrupting 
the normal TR-mediated signaling in target cells. By analogy with the estrogen 
receptors (ER) (Veld et al., 2006), and given the successful development of isotype 
selective TR ligands, these same chemicals could also transactivate each TR subtype in 
a selective manner (Schriks et al., 2007) contributing to tissue and developmental 
stage specific disorders. 
Assays attempting to discriminate between receptor subtype transcriptional effects 
have been previously reported, but these were restricted to green monkey fibroblasts 
(CV-1 cells) only transiently transfected with Xenopus TRs (Schriks et al., 2007), yeast 
reporter assay systems (Shiizaki et al., 2010) or the rat PC12 cell line expressing the 
avian TR!1 isoform (Jugan et al., 2007). Recently, we developed a stable transfected 
reporter gene assay based on the human pituitary adenoma GH3 cell line (Freitas et 
al., 2011) that is also used as basis for the T-screen (Hohenwarter et al., 1996; Gutleb et 
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al., 2005). The stably transfected GH3.TRE-Luc cells allow sensitive and rapid 
screening of TR agonists and antagonists (Freitas et al., 2011). Given that TR" appears 
to be the more abundant TR form present in GH3 cells  (Hahn et al., 1999) the stably 
transfected GH3.TRE-Luc cells is likely to detect especially TR" mediated responses. 
This implies that a stable TR! specific reporter gene assay in a human cell line is 
missing. To allow future high-throughput identification of potential TR!1 specific 
compounds, in the present study we developed a new stably transfected bioassay 
based on the human uterine cervical cancer cells (HeLa). The cells were stably co-
transfected with the receptor subtype TR!1 and the same TR-regulated reporter gene 
vector used for the development of the GH3.TRE-Luc cell line. For validation of the 
TR-specificity of the stably transfected TR!-HeLa.Luc and GH3.TRE-Luc cell lines, 
their responses to model isoform-selective ligands (CO23 and GC-1) (Chiellini et al., 
1998; Ocasio and Scanlan, 2006) were compared with the rank order of potency in 
transient TR isoform-specific reporter gene assays we established in the HeLa cell line. 
In addition to 7 known TR-active standards, 10 chemicals suspected to have TR 
disrupting activity, were also tested for their potential TR subtype specificity. 
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MATERIALS AND METHODS 
 
Chemicals. All chemicals were of ≥98% purity unless stated otherwise. 3,3$,5-triiodo-
L-thyronine (T3, CAS no. 6893-02-3), 3,3$,5,5’-tetraiodo-L-thyronine (T4, CAS no. 51-48-
9), 3,5,3',5'-tetraiodothyroacetic acid (Tetrac, CAS no. 67-30-1), 3,5,3'-triiodothyroacetic 
acid (Triac, CAS no. 51-24-1), 9-cis-retinoic acid (CAS no. 5300-03-8), 2-butyl-3-
benzofuranyl-4-(2-(diethylamino)ethoxy)-3,5-diiodophenyl ketone hydrochloride 
(Amiodarone, CAS no. 19774-82-4) and sodium arsenite (CAS no. 7784-46-5) were 
purchased from Sigma-Aldrich Chemie B.V. (Zwijndrecht, Netherlands) and 4,4’-
diiodobiphenyl (DIB, CAS no. 3001-15-8) from ABCR GmbH & Co (Karlsruhe, 
Germany). 2,4,4'-Tribromodiphenyl ether (BDE 28, CAS no. 41318-75-6), 
2,2$,3,3$,4,4$,5,5$,6-nonabromodiphenyl ether (BDE 206, CAS no. 63387-28-0), T3-like 4’-
hydroxy-2,3’,4,6-tetrabromodiphenylether (4-OH-BDE 69, CAS no. 218303-98-1) were 
kindly provided by Åke Bergman (Stockholm University, Sweden). (2-Butyl-1-
benzofuran-3-yl)-[4-(2-ethylaminoethoxy)-3,5-diiodophenyl]methanone (Desethyl-
amiodarone, CAS no. 83409-32-9) and 2-butyl-3-[4-[3-(butylamino)propoxy]benzoyl]-
5-benzofuranyl]-methanesulfonamide (Debutyldronedarone, CAS no. 141626-35-9) 
were a kind gift from Anita Boelen (Amsterdam University, The Netherlands). 2-[4-
({3-[2-(4-aminophenyl)ethynyl]-4-hydroxy-5-(propan-2-yl)phenyl}methyl)-3,5-dime-
thylphenoxy] acetic acid (NH-3, CAS no. 447415-26-1), 5-({4-[4-Hydroxy-3-(propan-2-
yl)phenoxy]-3,5-diiodophenyl}methyl)imidazolidine-2,4-dione (CO23, CAS no. 9116 
89-00-4) and 2-(4-{[4-hydroxy-3-(propan-2-yl)phenyl]methyl}-3,5-dimethylphenoxy) 
acetic acid (GC-1, CAS no. 211110-63-3) were kindly provided by Thomas S. Scanlan 
(Oregon Health Sciences University, USA) and synthesized as previously described 
(Chiellini et al., 1998; Nguyen et al., 2002; Ocasio and Scanlan, 2006). All compounds 
were dissolved in dimethylsulfoxide (DMSO, 99.9%; Acros Organics, Geel, Belgium) 
and kept in the dark. Stocks were stored at −20&C until used. Figure 1 illustrates the 
chemical structure of the compounds used in this study. 
 
Plasmids. The carrier DNA pBluescript SK- (Genbank Accession# X52324) was 
purchased from Promega (Madison, WI) and the green fluorescent protein (GFP) 
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vector pCS-GFP3 was a kind gift from Enrique Amaya (University of Manchester, 
UK). The TR-regulated luciferase reporter plasmids pGL4CP-SV40-2xtaDR4 and 
pGL4CP-TK-2xtaDR4 (courtesy of Michael L. Goodson and Martin Privalsky, 
University of California, Davis, USA) and the TR!1 and TR"1 expression vectors pCI-
neo-TR!1 and pCI-neo-TR"1 (provided by Ivan H. Chan and Martin Privalsky, 
University of California, Davis, USA) were designed as previously described (Chan 
and Privalsky, 2009; Freitas et al., 2011). 
 
Transfections. In transiently transfected cells, the maximal T3-induced luciferase 
activity using the pGL4CP-SV40-2xtaDR4 reporter gene vector was approximately 6× 
higher than cells transfected with pGL4CP-TK-2xtaDR4 (data not shown). Without the 
pCI-neo-TR!1 vector, the luciferase induction in the HeLa cells transiently transfected 
with pGL4CP-SV40-2xtaDR4 displayed a more than 30× lower fold-induction to T3 
compared to cells transfected with both plasmids (data not shown). Given the low 
endogenous TR activity and the superior induction factor of the SV40 based reporter 
gene, HeLa cells were stably transfected with the expression vector pCI-neo-TR!1 and 
the reporter plasmid pGL4CP-SV40-2xtaDR4 to create the TR!.HeLa-Luc cell line. 
The stable cell line GH3.TRE-Luc was prepared as previously described (Freitas et al., 
2011). The human uterine cervix cancer cell line (HeLa) was routinely sub-cultured 
once a week in fresh Minimum Essential Medium (MEM, Gibco, Paisley, Scotland) 
supplemented with 10% Fetal Calf Serum (FCS, Gibco, Paisley, Scotland) and 2 mM L-
glutamine (Gibco, Paisley, Scotland) in 75 cm2 culture flasks (Corning, Schiphol-Rijk, 
The Netherlands), in a humid atmosphere at 37°C and 95% air/5% CO2. Twenty-four 
hours before transfection, cells were seeded in regular growth medium into new 75 
cm2 culture flasks at a density of 3×106 cells per flask. Transfections were performed 
with Lipofectamine 2000 according to the manufacturer’s instruction (Invitrogen, 
Paisley, Scotland). The responsiveness of the reporter gene vectors pGL4CP-SV40-
2xtaDR4 and pGL4CP-TK-2xtaDR4, containing different minimal promoters driving 
the TR-dependent luciferase expression, were compared. Cells were transfected with 3 
(g of each desired vector (pCS-GFP3; pGL4CP-SV40-2xtaDR4 or pGL4CP-TK-
2xtaDR4; and pCI-neo-TR!1 or pCI-neo-TR"1) and pBluescript SK- as filler DNA, up 
to a total of 15 (g per flask. Six hours after transfection, cells were allowed to recover 
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Figure 1. Chemical structures of A) 3,3$,5-triiodo-L-thyronine (T3), B) 3,3$,5,5’-tetraiodo-L-thyronine (T4), C) 
5-({4-[4-hydroxy-3-(propan-2-yl)phenoxy]-3,5-diiodophenyl}methyl)imidazolidine-2,4-dione (CO23), D) 2-
(4-{[4-hydroxy-3-(propan-2-yl)phenyl]methyl}-3,5-dimethylphenoxy) acetic acid (GC-1), E) 3,5,3'-
triiodothyroacetic acid (Triac), F) 3,5,3',5'-tetraiodothyroacetic acid (Tetrac), G) T3-like 4’-hydroxy-2,3’,4,6-
tetrabromodiphenylether (4-OH-BDE 69), H) 9-cis-retinoic acid, I) 2,2$,3,3$,4,4$,5,5$,6-nonabromodiphenyl 
ether (BDE 206), J) 2,4,4'-tribromodiphenyl ether (BDE 28), K) 4,4’-diiodobiphenyl (DIB), L) 2-butyl-3-
benzofuranyl-4-(2-(diethylamino)ethoxy)-3,5-diiodophenyl ketone hydrochloride (Amiodarone), M) 2-
butyl-1-benzofuran-3-yl)-[4-(2-ethylaminoethoxy)-3,5-diiodophenyl]methanone (Desethylamiodarone), N) 
2-butyl-3-[4-[3-(butylamino)propoxy]benzoyl]-5-benzofuranyl]-methanesulfonamide (Debutyldroneda-
rone), O) 2-[4-({3-[2-(4-aminophenyl)ethynyl]-4-hydroxy-5-(propan-2-yl)phenyl}methyl)-3,5-dimethyl-
phenoxy] acetic acid (NH-3). 
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in phenol red-free Dulbecco’s Modified Eagle’s medium/Ham’s F12 (DMEM:F12, 
Gibco, Paisley, Scotland) supplemented with 5% dextran-coated charcoal-treated Fetal 
Calf Serum (DCC-FCS, HyClone), for 24 hours before exposure. 
For development of stable transfectants, transient transfected cells were transferred 
1:10 into fresh growth medium (MEM with 10% FCS and 2 mM L-glutamine) 24 hours 
after transfection. Forty-eight hours post-transfection, standard growth medium was 
replaced with selective medium containing 400 µg/ml of geneticin (Gibco, Paisley, 
Scotland). Single geneticin resistant colonies were harvested using cloning rings and 
allowed to proliferate until 100% confluency in 12-well plates. The clone with the 
highest inducible luciferase activity was selected by plating cells at 100% confluency 
in white clear bottom 96-well microplates (Packard View-Plate, PerkinElmer, 
Groningen, The Netherlands) and exposing to 0, 1, 10 and 100 nM of T3 for 24 hours. 
Luciferase activity was determined as described below. 
 
Stable or transient luciferase reporter gene assays. Stably transfected TR!.HeLa-
Luc cells were seeded at 80% confluency in 75 cm2 culture flasks in MEM 
supplemented with 10% FCS and 400 µg/ml of Geneticin. Twenty-four hours later, 
medium was replaced with phenol red-free DMEM:F12 containing 5% DCC-FCS for 
an additional period of 24 hours. Cells were then harvested by trypsinization and 
seeded into white clear bottom 96-well plates at a density of 3×104 cells per well and 
incubated for 24 hours with or without the indicated test chemical added from a 2× 
concentrated stock solution in DMSO. 
The GH3.TRE-Luc assay was performed as described (Freitas et al., 2011) with 
modifications. Cells were seeded at 80% confluency in 75 cm2 culture flasks in 
DMEM:F12 supplemented with 10% FCS and 320 µg/ml of geneticin. Twenty-four 
hours later, medium was replaced with phenol red-free DMEM:F12 containing 5% 
DCC-FCS for an additional period of 24 hours. Cells were then harvested by 
trypsinization, instead of scraping. Subsequently, cells were seeded into white clear 
bottom 96-well plates at a density of 3×104 cells per well and exposed for 24 hours to 
dilutions of the compounds added from a 2× concentrated stock solution in DMSO to 
culture medium. 
Transient transfected HeLa cells were harvested by trypsinization, 24 hours after 
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recovery of the transfection. Cells were then seeded in phenol red-free DMEM:F12 
supplemented with 5% DCC-FCS into white clear bottom 96-well plates at a density of 
3×104 cells per well and exposed for 24 hours. 
Both stably and transiently transfected cells were exposed in the presence (1 nM) or 
absence of T3. The DMSO concentration in exposure medium was kept the same for all 
exposures within an experiment, in all cases ≤0.2% (v/v). A T3 standard curve ranging 
from 0 to 100 nM was included in each experiment, in addition to 3 calibration points 
(0, 1 nM and 100 nM T3) included on all exposure plates. 
 
Cell viability and luciferase activity measurements. Cell toxicity and proliferation 
were determined per well in each exposure microplate by measuring total cellular 
metabolic activity using the reduction of resazurine to the fluorescent resorufin as 
previously reported (O'Brien et al., 2000; Schriks et al., 2006). For the GH3.TRE-Luc 
cells serum free medium (PCM) yielded the highest induction factor because of the 
very low baseline levels of luciferase expression. The stable TR!.HeLa-Luc cells, 
however, did not perform well in serum free medium (data not shown), with a high 
degree of well-to-well variation. Therefore, in order to make valid comparisons, both 
cell lines were exposed in medium (DMEM:F12) without phenol red and 
supplemented with DCC-FCS to reduce background induction by low levels of 
thyroid hormones present in FCS (Cao et al., 2012). To the exposure medium of each 
well 10 µl of a 400 µM resazurine (Sigma-Aldrich Chemie B.V., Zwijndrecht, Nether-
lands) solution was added and after 2 hours of incubation in the dark (37 °C; 95% 
air/5% CO2) fluorescence was measured at *ex = 530 nm and *em = 590 nm (Milli-
pore Cytofluor 2350 Fluorescence Measurement System). Subsequently, the same 
plates were used for luciferase determination. Cells were lysed in low salt buffer (10 
mM Tris, 2 mM DTT and 2 mM CDTA; pH 7.8) or lysis buffer (25 mM Tris, 2 mM 
DTT, 2 mM CDTA, 10 glycerol and 1% Triton x-100; pH 7.8) and luciferase activity 
was measured using the glow methodology, in a microplate luminometer with two 
injectors (Thermo LabSystems luminoskan Ascent) (Murk et al., 1998). For 
measurement of luciferase activity a glow instead of a flash luminescence type assays 
was used since in the GH3.TRE-Luc line T3-like 4-OH-BDE 69 was able to induce a 
76% T3-maximum response in the glow assay against a maximum of only 22% in the 
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flash assay, with similar EC50 of 431±33 nM and 391±27 nM respectively (data not 
shown). Flash luminescence is based on a short-lived reaction that generates a rapid 
peak of measurable light within seconds, while glow luminescence is supported by a 
slower rate reaction producing a stable signal for up to several minutes. Since no other 
differences were found, the glow methodology was used in further measurements. 
Furthermore, since GH3.TRE-Luc cells display a slight T3-dependent cell proliferation 
during the 24 h exposure (Freitas et al., 2011), a phenomenon not observed for the 
TR!.HeLa-Luc cells, all luciferase activities were normalized to the number of cells 
present at the end of the 24 hours incubation. 
 
Data and statistical analysis. Data shown correspond to the mean ± standard 
deviation (SD) of three independent experiments expressed as relative light units. 
Absolute values for the vehicle control (DMSO) were subtracted for all data on the 
same plate. 
The dose-response curves were characterized by the half maximal effect concentration 
(EC50). Triiodothyronine equivalence factors (T3EF50) for each compound were 
determined as the ratio between the EC50 of T3 and the EC50 of the compound. 
Compounds are considered to be not active when the response is lower than the 
vehicle control plus 2× the standard deviation, which was defined as limit of detection 
(Veld et al., 2006). 
Percentages of maximal luciferase induction for each test compound were calculated 
by setting luciferase response to solvent control (DMSO) as 0% and the maximum 
luciferase induction by T3 as 100% in the same experiment. The induction factor is 
calculated as the highest response divided by the response of the solvent control, after 
subtraction of the plate background. 
Statistical significance was tested by one-way analysis of variance (ANOVA), 
followed by Student-Newman-Keuls test. Differences were considered significant at 
p<0.05. Curve fitting and EC50 values were computed using GraphPad Prism version 5 
for Mac OSX (GraphPad Software, San Diego California USA, www.graphpad.com). 
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RESULTS 
 
HeLa cells were stably transfected with the expression vector pCI-neo-TR!1 and the 
reporter plasmid pGL4CP-SV40-2xtaDR4 to create the TR!.HeLa-Luc cell line. Clones 
were obtained via geneticin selection. The experimental conditions for chemical 
exposures and luciferase activity measurements were thoroughly optimized. Both 
stably transfected HeLa-based TR!.HeLa-Luc and GH3-based GH3.TRE-Luc cell lines 
responded to T3 in a dose-dependent manner (Figure 2A), with the maximum 
induction reached at 100 nM of T3 in each line. 
 
Figure 2. TR!.HeLa-Luc (o) and GH3.TRE-Luc (+) induction after 24 h exposure to A) T3 and B) T4. 
Luciferase activity expressed relative to T3 maximal induction (at 100 nM set at 100%, DMSO set at 0%). 
Data represent mean ± SD of triplicate experiments. 
 
Based on the EC50 level T3 was approximately 7× more potent in the GH3.TRE-Luc 
compared to the TR!.HeLa-Luc cells (table 1) and comparable to the EC50’s of the 
transiently transfected cells (t)TR!.HeLa-Luc and (t)TR".HeLa-Luc respectively 
(Table 1, Figures 3B and 4B). 
The potency of T4 was 2.7 fold less in the TR!.HeLa-Luc compared to the GH3.TRE-
Luc cells (Table 1, Figure 2B), reaching a maximum induction of approximately 90% 
of T3-maximum response in both assays. The average coefficient of variation (CV) of 
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triplicate measurements is 5% for all compounds in both cell lines. 
To examine whether the TR!.HeLa-Luc and GH3.TRE-Luc lines can discriminate 
between known subtype selective ligands, we used the ! and "-selective agonists, 
CO23 and GC-1 respectively (Chiellini et al., 1998; Ocasio and Scanlan, 2006). Both 
compounds were able to induce a full dose-response curve up to 80% induction of T3-
maximum response in both stable cell lines (Figures 3A and 4A), but the TR!-
selective agonist CO23 had a 2.8× lower EC50 in the TR!.HeLa-Luc than in the 
GH3.TRE-Luc cells. In the TR!.HeLa-Luc cells the "-selective agonist GC-1 had a 10× 
higher EC50 than in the GH3.TRE-Luc cells (Table 1). 
 
Table 1. EC50 (half maximal effective concentration), T3EF50 (triiodothyronine equivalence factors) and 
maximal induction (expressed relative to T3 set at 100%) values determined in the stably transfected cell 
lines TRa.HeLa-Luc and GH3.TRE-Luc. Each experiment was performed at least three times in triplicate. 
 
 
Compound 
 TR!.HeLa-Luc  GH3.TRE-Luc T3EF50!/ 
 EC50 (nM) 
T3EF50 Max. induction 
(%)  
EC50 
(nM) 
T3EF50 Max. induction 
(%) T3EF50" 
          
T3  4.4±0.6 1 100 (100nM)  0.6±0.08 1 100 (100nM) 1 
T4  52±11 0.08 94  19±3 0.03 88 2.7 
Triac  0.4±0.09 11 93  0.2±0.08 3.8 92 3.0 
Tetrac  109±14 0.04 87  8.8±0.6 0.07 91 0.6 
4-OH-BDE69  155±23 0.03 26  431±33 0.001 78 20 
CO23  12±2 0.4 80  33±5 0.02 77 20 
GC-1  14±3 0.3 49  1.4±0.2 0.4 91 0.7 
9-cis-retinoic acid  - - 3.8  - - 19 - 
BDE206  - - -  - - - - 
BDE28  - - -  - - - - 
DIB  - - -  - - - - 
Antagonists IC50 in the presence of 1 nM T3 
          
NH-3  300±34  -31  112±19  -80 - 
Sodium Arsenite  94.4±11  -98  2.4±0.8  -99 - 
Amiodarone  - - -  - - - - 
Desethylamiodarone  - - -  - - - - 
Debutyldronedarone - - -  - - - - 
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Figure 3. Luciferase induction in A) TR!.HeLa-Luc and B) transiently transfected (t)TR!.HeLa-Luc cells 
after 24 h exposure to T3 (+), CO23 (,) and GC-1 (▲). Luciferase activity expressed relative to T3 maximal 
induction (at 100 nM set at 100%, DMSO set at 0%). Data represent mean ± SD of triplicate experiments. 
 
 
Figure 4. Luciferase induction in A) GH3.TRE-Luc and B) transiently transfected (t)TR".HeLa-Luc cells 
after 24 h exposure to T3 (+), CO23 (,) and GC-1 (▲). Luciferase activity expressed relative to T3 maximal 
induction (at 100 nM set at 100%, DMSO set at 0%). Data represent mean ± SD of triplicate experiments. 
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In GH3.TRE-Luc cells, GC-1 essentially induced the T3-maximum response (91%) 
against a maximum of only 49% in the TR!.HeLa-Luc cell line. Therefore, the potency 
rank for the selective agonists compared to T3 was as expected, with T3>CO23>GC-1 
for TR!.HeLa-Luc and T3>GC-1>>CO23 for the GH3.TRE-Luc cells. These findings 
are also supported by examining dose response curves in transiently (t) transfected 
HeLa cells exposed to the same ! and "-selective agonists displayed the same order of 
relative potencies, T3>CO23>GC-1 for (t)TR!.HeLa-Luc and T3>GC-1>CO23 for 
(t)TR".HeLa-Luc (Table 2, Figure 3B and 4B). 
 
Table 2. EC50 (half maximal effective concentration), T3EF50 (triiodothyronine equivalence factors) and 
maximal induction (expressed relative to T3 set at 100%) values determined in the transiently (t) transfected 
cell lines TRa.HeLa-Luc and TRb.HeLa-Luc. Each experiment was performed at least three times in 
triplicate. 
 
Compound 
(t)TR!.HeLa-Luc (t)TRb.HeLa-Luc T3EF50!/ 
EC50 
(nM) T3EF50 
Max. 
induction 
(%) 
EC50 
(nM) T3EF50 
Max. 
induction 
(%) 
T3EF50" 
T3 1.1±2 1 100 (10nM) 3.5±3 1 100 (100nM) 1 
CO23 2.6±3 0.4 82 24±6 0.1 101 2.8 
GC-1 15±4 0.07 59 11±4 0.3 94 0.2 
 
Figure 5. TR!.HeLa-Luc (o) and GH3.TRE-Luc (+) induction after 24 h exposure to A) Triac and B) Tetrac. 
Luciferase activity expressed relative to T3 maximal induction (at 100 nM set at 100%, DMSO set at 0%). 
Data represent mean ± SD of triplicate experiments. 
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Having established the relative subtype selective responsiveness of the two stable 
reporter lines, we next examined a series of other chemicals known to induce TR-
mediated gene expression. The acetic acid derivatives of T3 and T4, Triac and Tetrac 
are as potent as their natural parent compounds (Table 1, Figure 5), and both 
compounds are most potent in GH3.TRE-Luc line. Interestingly, Tetrac was less 
potent than T4 in the TR!.HeLa-Luc cell line, but more potent than T4 in the in 
GH3.TRE-Luc cells. 9-cis-retinoic acid significantly induced luciferase activity up to 
19% of the T3-maximum response in the GH3.TRE-Luc cells but poorly if at all in the 
TR!.HeLa-Luc cells (Figure 6), whether or not T3 was also present in the media. 
 
Figure 6. Luciferase induction in GH3.TRE-Luc (black bars) and TR!.HeLa-Luc (white bars) cells after 24 h 
exposure to 9-cis-retinoic acid. Luciferase activity expressed relative to T3 maximal induction (at 100 nM set 
at 100%, DMSO set at 0%). Data represent mean ± SD of triplicate experiments. 
 
The T3-like 4-OH-BDE 69, a model hydroxylated BDE synthesized for high binding 
affinity for the receptor (Marsh et al., 1998), was able to induce luciferase activity in 
both cell lines (Figure 7), inducing 78% of T3-maximum response in the GH3.TRE-Luc 
cells against a maximum of only 26% in the TR!.HeLa-Luc cell line, contrasting with 
the almost 3× lower potency in the GH3.TRE-Luc cells (Table 1). 
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Figure 7. TR!.HeLa-Luc (o) and GH3.TRE-Luc (+) induction after 24 h exposure to 4-OH-BDE 69. 
Luciferase activity expressed relative to T3 maximal induction (at 100 nM set at 100%, DMSO set at 0%). 
Data represent mean ± SD of triplicate experiments. 
 
We next compared the responsiveness of compounds reported to have antagonistic 
activity against TR mediated gene expression; NH-3, a designed antagonist that binds 
directly to the receptor (Lim et al., 2002; Nguyen et al., 2002) and sodium arsenite, an 
environmentally relevant compound with a less understood mode of action (Davey et 
al., 2007). In the TR!.HeLa-Luc cell line, the antagonist NH-3 slightly but significantly 
decreased (31%) luciferase activity induced by 1 nM of T3 after an initial induction of 
13% at 10 nM. By contrast, NH-3 strongly antagonized T3-induced luciferase activity 
(80%) in the GH3.TRE-Luc cells (Table 1, Figure 8A). The inhibitor sodium arsenite 
completely inhibited T3-induced luciferase activity at 100 (M in both cell lines without 
any signs of cytotoxicity, but with a much lower IC50 in the GH3.TRE-Luc cells (Table 
1, Figure 8B). 
By contrast, amiodarone and its metabolite desethylamiodarone, and debutyldro-
nedarone, compounds previously reported to antagonize TR activity (Latham et al., 
1987; Van Beeren et al., 2003; Schriks et al., 2006), did not induce any effect on 
luciferase activity in either cell line, both in the presence or absence of T3. Likewise, 
DIB, an organic photo-conductor reported to induce luciferase activity in a reporter 
cell line endogenously expressing the human TR! (Yamada-Okabe et al., 2005), did 
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not have an effect in either of the cell lines here. Lastly, the brominated flame-
retardants BDE 28 and BDE 206 (Schriks et al., 2007) also did not induce any effect on 
luciferase activity in either cell line, whereas these compounds have been previously 
reported to have variable agonist or antagonist activity in the T-screen and/or 
transient and stable transfection based assays (Table 1). 
 
Figure 8. TR!.HeLa-Luc (white bars) and GH3.TRE-Luc (black bars) induction after 24 h exposure to a) 
NH3 and B) Sodium Arsenite. Luciferase activity expressed relative to T3 maximal induction (at 100 nM set 
at 100%, DMSO set at 0%). Data represent mean ± SD of triplicate experiments. *Significantly different from 
control (*p < 0.05, **p < 0.01 and ***p < 0.001). 
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DISCUSSION 
 
n this study we developed and validated a stable in vitro human reporter gene 
assay to elucidate the receptor-ligand interactions of the ! and " TR subtypes. 
This was achieved through the development of a human uterine cervical HeLa cell 
line stably co-transfected with the human TR subtype alpha 1 (TR!1) and a TRE-
regulated luciferase reporter gene designated TR!.HeLa-Luc. The TR-mediated 
responses of this cell line were compared with the previously reported GH3.TRE-Luc 
cells (Freitas et al., 2011) with TR" appearing to be the dominant endogenous TR 
isoform (Hahn et al., 1999). Although at low levels, TRs are also expressed in wild-
type HeLa cells, such that transient transfection of the TR-dependent reporter gene 
vector resulted in a low but quantifiable induction of luciferase activity (data not 
shown); however, co-transfecting the TR!1 expression vector resulted in a 30-fold 
greater magnitude of response, increasing the TR! specificity of the assay. Previous to 
the development of the stable cell line, the degree of each TR-isotype specific nature 
was determined via transiently transfection assays expressing human TR! or TR" in 
HeLa cells, with high quality dose-response curves (Figures 3B and 4B). Although 
great improvements have been made to standardize transient transfections for 
detecting TR modulating chemicals (Hofmann et al., 2009), we focused on the use of a 
stably transfected cell lines to avoid the many steps required in the preparation of a 
transient assay. Although the preparation of a stable reporter gene assay is time 
consuming and does not always yield well performing cell lines, the experimental 
variability and cost associated with transient reporter genes assays make the stable 
assays the most suitable option for high-throughput screening applications. 
Multiplexing in the same cell culture plate cellular viability and luciferase activity 
measurements enables a further reduction of total assay time. 
Assays attempting to discriminate between receptor subtype transcriptional effects 
have been previously reported, but these were restricted to green monkey fibroblasts 
(CV-1 cells) only transiently transfected with Xenopus TRs (Schriks et al., 2007), yeast 
reporter assay systems (Shiizaki et al., 2010) or the rat PC12 cell line expressing the 
avian TR!1 isoform (Jugan et al., 2007). Recently, we developed a stable transfected 
I 
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reporter gene assay based on the TR" dominant human pituitary adenoma GH3 cell 
line (Freitas et al., 2011) which allows sensitive and rapid screening of TR agonists and 
antagonists. Given that TR" is apparently more abundant TR form present in GH3 
cells (Hahn et al., 1999) the stably transfected GH3.TRE-Luc cells is likely to detect 
especially TR" mediated responses. This implies that the stable TR!.HeLa-Luc cells 
developed in the present study complete a set of in in vitro TR specific reporter gene 
assays in human cell lines. The established in vitro bioassay based on TR!.HeLa-Luc 
cells enabled the detection of T3 in the picomolar range within only 24 hours of 
exposure, with a detection limit of 100pM. Compared to a TR-mediated reporter gene 
assay in yeast, this is an almost 8× lower EC50 (Shiizaki et al., 2010), and this difference 
between the human cell line based and the yeast based assay is comparable to 
differences between mammalian cell- and yeast-based reporter gene assays for 
estrogen-receptor mediated responses (Legler et al., 2002). Another stably transfected 
reporter gene assay based on the rat PC12 cell line that constitutively expresses the 
avian TR!1 isoform responds to T3 with approximately the same sensitivity (Jugan et 
al., 2007). Although no striking mechanistic differences have been reported between 
avian and mammalian TR!1-mediated gene expression, one cannot exclude potential 
discrepancies due to qualitative and quantitative differences in receptor co-activators 
and co-repressors in different cellular contexts, or potential species specific compound 
interactions outside the well conserved ligand binding pocket (Wagner et al., 2001). 
Hence we chose to stably express a human TR isoform in a human cell line with 
typically low TR expression levels for these studies. 
The TR" dominant GH3.TRE-Luc cell line was stably transfected with the same TR-
regulated reporter gene vector used in the present study for the development of the 
TR!.HeLa-Luc cell line (pGL4CP-SV40-2xtaDR4). Both stable cell lines share the same 
experimental conditions, with the exception of their respective routine sub-culture 
media formulations. In order to keep the exposure conditions the same between cell 
lines, for direct comparison of their response profiles, a common medium with 5% 
DCC-FCS was used for all exposures. This allowed a similar T3-induced dose-
dependent response (Figure 2A and 3A), with the GH3.TRE-Luc cells slightly more 
sensitive than the TR!.HeLa-Luc cells. In agreement with other studies, while the 
binding affinity of TR! or TR" is virtually identical, TR!-mediated responses induced 
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by T3 are consistently more sensitive (at the EC50 level) than TR"-mediated responses 
in our transient transfection assays. Thus, the higher sensitivity of the TR" dominant 
GH3.TRE-Luc line is most likely due to differences in cellular context, such as 
coregulator expression, deiodinase activity or TH transport. 
Differences in potency or maximal luciferase induction relative to T3 were not found, 
except for the T3-like 4-OH-BDE 69 in the GH3.TRE-Luc line. Further validation of the 
stable receptor subtype dominant reporter gene cell lines was performed with the 
model isotype-selective ligands CO23 and GC-1. The two stable cell lines as well as 
HeLa cells transiently transfected with either TR isoforms (TR!1 or TR"1), were 
exposed in parallel with these receptor subtype selective chemicals. The transient 
transfections and exposures to CO23 and GC-1 allow a functional assessment and 
validation of the receptor variant discriminatory differences between in each stable 
cell line. As anticipated, the TR!-selective CO23 was more potent in the transient and 
stable TR!. HeLa-Luc cells contrasting with the higher potency of the TR"-selective 
GC-1 in the transient and stable GH3.TRE-Luc cells. This is also reflected by the 
T3EF50!/T3EF50" ratios (2.8 and 20 for CO23, 0.2 and 0.7 for GC-1) indicating their 
respective relative affinity towards TR! and TR". In accordance with previous reports 
(Wagner et al., 2001), these differences are mainly due to the way each ligand interacts 
with a single different amino acid in the ligand binding domains of the otherwise 
homologous TR! and TR" receptor ligand binding domains. Likewise, the T3-like 4-
OH-BDE 69 revealed a relatively increased potency towards the TR! cell line 
(T3EF50!/T3EF50" ratio of 20), making a good candidate for further in vivo testing due 
to possible different physiological effects in TR! versus TR" dominant tissues. 
Other chemicals suspected to be TR ligands were tested for their TR-isoform specific 
responses. The selected chemicals had all previously shown to mediate TR-dependent 
effects as agonists or antagonists. However, their ligand potencies and specificities to 
TR subtypes were slightly different. For instance, the potencies of the natural thyroid 
hormone T4 and the acetic acid derivatives of T3 and T4 (Triac and Tetrac, respectively) 
were consistent with previous reports (Cheek et al., 1999; Gutleb et al., 2005). 
Interestingly, Tetrac was more potent than T4 in the TR"-dominant GH3.TRE-Luc cells 
as previously reported using a biochemical assay with either TR! or TR" in the 
presence of SRC1-2 co-activator peptide (Koury et al., 2009). The type I and II 5'-
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deiodinases are both expressed in the GH3 cells (Baur et al., 2000; Mori et al., 2007), 
playing an important role in the regulation of hormone production. These enzymes 
are capable of deiodinating the outer ring of both T4 and Tetrac, which converts them 
to their active form T3 and Triac. Specifically for these chemicals, different levels of 
expression of these enzymes in the TR!.HeLa-Luc and the GH3.TRE-Luc cells could 
account for the differences in potency. A similar reasoning applies for 9-cis-retinoic 
acid, which is a known ligand of the TR normally silent heterodimer partner RXR (Li 
et al., 2002). A permissive TR-RXR partnership may occur in the GH3 cells enabling 
the activation of the stably transfected TRE-Luc system by this retinoid, even in the 
absence of T3, as has been proposed for the prolactin gene TRE (Castillo et al., 2004). In 
the HeLa cells, luciferase expression may be triggered by a ligand activated TR!1 
monomer, homodimer, or as a TR/RXR heterodimer where RXR is less permissive, 
possibly due to the lack or presence of particular cofactors that enable the non-silent 
behavior in certain cell types, or potentially lower RXR expression than GH3 cells. 
Therefore differences in cellular contexts should be taken into account when 
interpreting the different TR-related effects of the same compound in TR!.HeLa-Luc 
vs. GH3.TRE-Luc cells. 
We also found differential sensitivity of these two lines to two mechanistically 
different antagonistic compounds. The designed antagonist NH-3 that competitively 
inhibits TH binding to the receptor was most potent in the GH3.TRE-Luc cells. This 
suggests isotype selectivity even though NH-3 binds to TR! and TR" equivalently 
(similar EC50). Interestingly, data from our laboratory suggests that NH-3 is a less 
effective antagonist in TR! dominated tissues than TR" dominated tissues in Xenopus 
laevis tadpoles (Neff et al. unpublished results). In accordance with previous studies 
(Davey et al., 2007) the inhibitor sodium arsenite also disrupted the TR-mediated 
luciferase expression at non-cytotoxic concentrations, implying a common inhibitory 
mechanism of action for both cell lines. As with NH-3, a clear selectivity towards 
inhibition of T3 induced reporter gene activity in the TR" dominant GH3.TRE-Luc 
cells was also observed for sodium arsenite but much less is known about its mode of 
action. 
Together, the stably transfected GH3.TRE-Luc and TR!.HeLa-Luc reporter gene cell 
lines described here complement each other by enabling simple, rapid and specific 
Chapter 5 
 146 
identification of chemicals that modulate TR activity in an isotype-selective manner. 
Further comparisons of the GH3.TRE-Luc and the TR!.HeLa-Luc cell lines in terms of 
deiodinases, TR coregulators, heterodimer partners and transporters will be 
important to allow additional differentiation between truly TR-mediated effects and 
molecules indirectly affecting the receptors in an isotype selective manner, and their 
further development as front-line rapid screens for TR disrupting compounds. 
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SUMMARY 
 
he aim of the present thesis was to develop functional in vitro bioassays for the 
detection of compounds affecting thyroid hormone signaling at the level of the 
thyroid hormone receptor. The assays to be developed should be appropriate for 
quantitative high-throughput screening (qHTS) and inclusion in an in vitro test 
battery, replacing the use of animal experiments in the identification of thyroid 
hormone disrupting compounds and quantification of their potency. 
In Chapter 1, background information and objectives of the thesis are presented. First 
it is explained that the thyroid hormone (TH) system is responsible for several 
important physiological processes, including regulation of energy metabolism, 
growth and differentiation, development and maintenance of brain function, thermo-
regulation, osmo-regulation, the onset and proper function of other endocrine 
systems, sexual behavior and fertility, and cardiovascular functioning. Given the 
relevance of the TH system, the concern about TH disruption (THD) has resulted in 
the development of in vitro strategies to identify THD compounds (THDCs). This 
information is generally derived from animal studies and, for the majority of 
chemicals present in the environment, quite limited or not available. For ethical, 
financial and practical reasons, in vitro and in silico alternatives are crucial for the 
identification of THDCs and quantification of their effects. THDCs may act by several 
different mechanisms of action, including altered hormone production, transport, 
metabolism, receptor activation and disruption of feedback mechanisms. For several, 
but not all of these endpoints, in vitro assays are already available. However, at the 
time of the start of this thesis no functional in vitro bioassay was available for 
detection of TR agonists and antagonists that also would be appropriate for 
quantitative high-throughput screening (qHTS) of potential THDCs. Thus the aim of 
the present study was to develop and validate functional in vitro bioassays for thyroid 
hormone receptor-mediated toxicity, focusing on thyroid hormone receptor 
interaction. 
Chapter 2 describes the development of a stable luciferase reporter gene assay based 
on the thyroid hormone responsive rat pituitary tumor GH3 cell line that 
T 
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constitutively expresses both thyroid hormone receptor isoforms, with TR! appearing 
to be the major TR isoform. The assay was established by stably transfecting the 
pGL4CP-SV40-2xtaDR4 construct into the GH3 cells resulting in a highly thyroid 
hormone sensitive cell line (GH3.TRE-Luc), which was further optimized into an 
assay that allowed the detection of triiodothyronine (T3) and thyroxine (T4) 
concentrations in the picomolar range after only 24 h of exposure. The greater than 20-
fold induction by T3 relative to the solvent control is illustrative of the high 
responsiveness of the system. The assay was validated by the quantification of the 
agonistic effect of the natural hormones (T3 and T4), the acetic acid derivatives of T3 
(triiodothyroaceticacid, Triac) and T4 (tetraiodothyroacetic acid, Tetrac), hydroxypoly-
brominated diphenylethers (OH-PBDEs), hydroxypolychlorinated biphenyls (OH-
PCBs) and the antagonistic action of sodium arsenite (NaAsO2). The putative 
antagonist amiodarone, and bisphenol A (BPA) and its halogenated derivatives 
(TCBPA and TBBPA) for which effects reported in the literature are not consistent, 
showed comparable dose-response curves with a slight agonistic effect (5% of T3-max) 
followed by a slight antagonistic effect. The magnitude and reproducibility of the 
responses to various compounds confirmed the assay to be a promising tool for the 
identification and quantification of specific thyroid hormone receptor active 
compounds. 
In Chapter 3 the use of the GH3.TRE-Luc reporter gene cell line for a quantitative 
high-throughput screening (qHTS) platform is described. The GH3.TRE-Luc assay 
was miniaturized and validated in a 1536-well plate format. Using this miniaturized 
format, the Library of Pharmacologically Active Compounds (LOPAC) and the 
National Toxicology Program (NTP) collection were screened for TR agonists and 
antagonists. Of the 2688 compounds tested 8 or 1 were identified as TR agonists 
depending on whether the positive hit cut off was defined at ≥10% or ≥20% of efficacy 
relative to T3, respectively, and 5 were identified as TR antagonists. None of the 
inactive compounds were structurally related to T3, nor reported elsewhere to be 
thyroid hormone disruptors, so false negatives were not detected. The low potency 
agonists also did not resemble the thyroid hormones, which is an indication that these 
may not be active directly through the ligand-binding domain of the receptor and 
Summary, general discussion and future perspectives 
 161 
may not represent effective agonists. Defining TR agonists in the qHTS using the 
criteria of a hit cut off of ≥20% efficacy at 100 #M may avoid identification of positives 
without physiological relevance. It is concluded that the miniaturized GH3.TRE-Luc 
assay is an important addition to the in vitro test battery for TR-mediated endocrine 
disruption, and that, given the low percentage of compounds testing positive, its 
high-throughput nature is an important advantage for future toxicological screening. 
After the GH3.TRE-Luc cells had shown to be highly responsive and suitable for the 
application in a qHTS test battery for detecting TH disrupting chemicals, a 
comparison was performed with the responses of bona fide endogenous TH target 
genes (Chapter 4). In addition to the TRE-driven luciferase induction in the GH3.TRE-
Luc cells, TH-dependent cell proliferation was also analyzed since the effect of some 
THDCs could be independent of the canonical TH signaling per se. In this study, we 
treated GH3 cells with T3 as well as two TR isotype (TR$ and TR!) selective 
thyromimetics, CO23 and GC-1 respectively. Response profiles in the reporter gene 
assay showed excellent concordance with endogenous growth hormone (GH) gene 
expression, a known direct TH target gene and the basis of the use of these cells in the 
proliferation based T-screen. Further, it was demonstrated that sodium arsenite, 
bisphenol A and the phthalate DEHP inhibit the T3-mediated induction of the reporter 
gene as well as the endogenous expression of the GH gene. A subsequently 
performed microarray experiment identified a fuller spectrum of T3 responsive genes 
in these cells, since promoter selective effects of synthetic nuclear receptor ligands 
may occur. In addition to identifying several important components of the TH 
signaling pathway, the microarray allowed identification of a battery of both known 
and novel TH target genes, including genes related to angiogenesis such as HIF2$ 
(EPAS1). Identification of these genes is important for validation of assays designed to 
identify new synthetic TR modulators and their potential genomic versus non-
genomic modes of action. 
Chapter 5 deals with the fact that the critical role of TH in processes such as brain 
development, growth and energy homeostasis is performed via different isoforms of 
the thyroid hormone receptor. As the main isoforms, TR$ and TR!, present distinct 
physiological functions, it is important to study the TR-specific potency of TH active 
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compounds. This chapter firstly describes the development of TR$ and TR! transient 
luciferase reporter gene bioassays using human cervical HeLa cells enabling 
quantification of the responses of the TR isoform-selective chemicals CO23 and GC-1. 
In conjunction with this, a stable TR$ specific reporter gene cell line was developed, 
denominated TR$.HeLa-Luc. Responses in this TR$.HeLa-Luc cell line were 
compared to responses in the GH3.TRE-Luc cell line, which appears to contain TR! as 
the major isoform. The TR isoform-selective chemicals CO23 and GC-1 induced 
responses according to the anticipated potency rank order T3>CO23>GC-1 in the 
TR$.HeLa-Luc cells and T3>GC-1>CO23 in the GH3.TRE-Luc cell line. In addition to 7 
known TR-active standards, 10 chemicals suspected to have TR disrupting activity 
were tested. Of these, only sodium arsenite and the T3-like 4-OH-BDE69 induced a 
response in the TR$.HeLa-Luc assay. Together, the developed TR$.HeLa-Luc and 
GH3.TRE-Luc stable reporter gene cell lines add a new level of specificity, 
representing an improvement of the available tools for in vitro high-throughput 
assessment of TR isoform-specific activity of drugs and environmental pollutants.
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GENERAL DISCUSSION AND FUTURE PERSPECTIVES 
 
s summarized above, this thesis presents the development of functional in 
vitro bioassays for the detection of compounds disrupting the thyroid 
hormone signaling at the level of the thyroid hormone receptor. These assays could be 
used in a battery of selected mechanism-specific high-throughput in vitro bioassays 
that could at least partially replace the use of animal experiments for the identification 
and quantification of specific thyroid hormone receptor disrupting activities of 
compounds. In this section, the advantages and limitations of the use of in vitro assays 
for replacing animal experiments are discussed in more detail with emphasis on the 
relevance of the developed TR-dependent reporter gene assays. 
 
OVERRATED VALUE OF ANIMAL EXPERIMENTS 
Information on the potency of THDCs is largely derived from animal studies. For the 
majority of chemicals, however, this information is limited or not available and 
performing animal experiments for all relevant chemicals is unlikely to happen in the 
near future for ethical, financial and practical reasons. Although in vivo bioassays are 
generally perceived as being the most reliable tests for assessing the risk of chemicals, 
including THDCs, to human health, this approach faces several limitations. For 
instance, healthy animals may cope with an exposure to THDCs by compensation via 
HPT feedback mechanisms or other means and effects may be masked, while humans 
with specific health conditions, such as hypo- or hyperthyroidism or malnutrition, 
may be more vulnerable. Also, since most in vivo studies are hardly ever carried until 
animals are fully mature, life-stage specific differences may be overlooked when 
assessing the risk for humans. Furthermore, it is of importance to note that although 
rodents and human share a common physiology for the HPT axis, several differences 
between rodents and human have been defined that make the rat more sensitive 
toward thyroid proliferative effects than human (Berthelsen et al., 2002; EFSA, 2011). 
The high affinity binding protein thyroxine-binding globulin (TBG) which binds T4 
and to a lesser degree T3, is present in humans but lacking in rodents, birds, 
amphibians and fish (Larsson et al., 1985). This implies that rodents have a higher 
A 
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percentage of unbound active T4 and T3 than humans, as well as higher degradation 
rates (lower half-life) for plasma T4. This difference in T4 half-life results in a 10-fold 
greater requirement for endogenous T4 in the rat thyroid than in the adult human 
thyroid and an accelerated production of thyroid hormone in the rat which is driven 
by serum TSH levels that are about 6- to 60-fold higher than in humans (EFSA, 2011). 
As a result, the rodent thyroid gland is chronically stimulated by TSH levels to 
compensate for the increased TH turnover. This may result in increased sensitivity of 
the thyroid gland toward increased growth and potential neoplastic change in rats 
than in humans, reflecting an important species difference. This makes the rat and 
rodent-based models sensitive models for hazard assessment of thyroid disruption 
although the species difference between rodents and human should be taken into 
account in subsequent risk assessment.  
Therefore, an appropriate in vitro test battery for hazard assessment on thyroid 
disruption should cover mechanisms relevant to different life stages and under 
different exposure conditions. They should enable fast assessment of a broad range of 
compounds for potential perturbations of the TH signaling pathways relevant for 
humans, with virtually no animals sacrificed and at much lower cost. Results based 
on in vitro testing also may offer the possibility to predict interspecies THD effects, 
provided that species-specific in vitro assays will be available taking into account 
species-specific physiological characteristics. 
In addition it is of importance to note that most current rodent-based assays were 
originally developed for the detection of the disrupting effects on the sex-hormone 
signaling system, and not optimized for the identification of THDCs. Relevant effects 
may not be detected in animal studies when the outcomes are delayed, life stage 
specific, not assessed (e.g. behavior) or only occur when an organism has to adapt to 
environmental factors by modulating TH levels. Therefore, in in vivo studies it is often 
difficult to determine whether the effect of a compound is a result of THD or another 
toxic mechanism. This may have critical consequences for policy decisions regarding a 
compound, as there is a tendency for a stricter regulation on endocrine disrupting 
compounds than toxic compounds affecting other mechanisms. 
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TR-MEDIATED THYROID HORMONE DISRUPTION 
The TRs control transcription of specific genes directly through interaction with 
thyroid hormone response elements (TREs). Typically, TRs form a complex with the 
retinoid X receptor (RXR), a heterodimer where the RXR is usually a “silent partner”. 
Nonetheless, in particular cell types and/or TRE configurations RXR may be ligand 
activated by specific retinoids (Castillo et al., 2004). In the GH3.TRE-Luc cell line 
(Chapter 2), the response to retinoids was consistent with a permissive heterodimer. 
In contrast, the TR$.HeLa-Luc cells did not show this effect of RXR activation and 
crosstalk with the RXR (Chapter 5). The results also imply that the agonist activity 
detected in the GH3.TRE-Luc cells may in some cases reflect RXR rather than TR 
agonist activity. It should be further studied whether a comparison between both cell 
lines could be used to filter out RXR-active compounds, reducing the chances of 
detecting false positives in the GH3.TRE-Luc assay. 
Recently, THs have also shown to directly act at the cell membrane, cytoplasm (Cheng 
et al., 2010) and mitochondria (Chocron et al., 2012; Pessemesse et al., 2012), which is 
of interest given the important influence of THs on mitochondrial function in warm-
blooded vertebrates. Often, these effects are referred to as non-genomic versus the 
“classical” nuclear receptor-mediated genomic effects described above. However, this 
may be a misnomer since actions initiated at the membrane or in the cytoplasm may 
ultimately influence the transcription of specific genes, and even interface with the 
action of the nuclear TRs. The actions of TH at the cell membrane, cytoplasm or 
mitochondria, may be mediated by a bona fide TR isoform acting outside the nucleus, 
a different form of the TR or a distinct receptor for TH signaling altogether. For 
example, T4 (and to some extent T3) can stimulate blood vessel formation 
(angiogenesis) in various models via an integrin-mediated signaling pathway (Cheng 
et al., 2010). 
While most TH disruption has shown to occur at pre-receptor stages such as TH 
production, regulation, plasma transport and metabolism, TRs are in the signaling 
pathway closest to the endpoints that result in altered cellular responses: 
transcriptional control of target genes. The relatively tight fit of the TR ligand-binding 
domain only allows compounds with a closely resembling structure to the hormone 
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itself to bind with reasonable affinity (DeVito et al., 1999; Zoeller, 2005) (Chapters 2 
and 3). As a result only few of the known THDCs have shown to directly bind to the 
receptor ligand-binding domain and interfere with the TR action. 
On the other hand, although chemical libraries such as the Library of Pharma-
cologically Active Compounds (LOPAC) and the National Toxicology Program (NTP) 
collection applied in the research described in this thesis (Chapter 3), or the recently 
screened Tox21 library (>10.000 compounds), comprise a diverse chemical space with 
chemicals proven to be pharmacologically active and almost all previously tested in 
one or more standard toxicological assays, they do not include chemicals known for 
their in vivo or in vitro THD potency. For example, OH-PHAHs (hydroxylated 
polyhalogenated aromatic hydrocarbons) such as TBBPA (4,4’-propane-2,2-
diylbis(2,6-dibromophenol)) or OH-PCBs (hydroxylated polychlorinated biphenyls), 
and PBDEs (polybrominated diphenylethers) shown before to be active in the 
GH3.TRE-Luc assay (Chapter 2) are not included in these libraries. 
It should also be emphasized, that the complexities of the transcriptional control by 
these receptors go beyond direct binding to the receptors or altering coactivator/ 
corepressor interactions and a multitude of other mechanisms for disruption of the 
receptor action are also possible. Interactions with RXRs may affect a subset of 
important TH target tissues or specific genes in specific cells. Furthermore, the TRs 
themselves and various coactivator and corepressor proteins are subject to post-
translational modifications that may be a target for endocrine disruption. TR and 
coactivator stability, nuclear localization, and interactions with other cofactors may be 
additional targets of THDCs. As an example, exposure to arsenic trioxide (Chapter 4) 
activates a MAP kinase cascade that leads to phosphorylation of the corepressor 
SMRT and its dissociation from the nuclear receptor complex may lead to 
derepression of target genes (Hong et al., 2001). This complexity is well embodied in 
the GH3 cells, which are used throughout the research described in this thesis, due to 
their extensive characterization, expression of both TR isoforms (mainly TR!), their 
heterodimer partners and respective cofactors, as well as deiodinase enzymes (Ball et 
al., 1997; Misiti et al., 1998; Baur et al., 2000). These and other possibly unknown 
transcription factors and enzymes may be absent in other cell-based systems resulting 
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in completely different responses to THDCs. Moreover, by coupling the increased 
level of cell proliferation and growth hormone secretion in response to physiological 
levels of THs with the TR-mediated luciferase activity, a better distinction can be 
made between TR-mediated and other mechanisms of action that induce cell 
proliferation, ultimately reducing the complexity that characterizes the multitude of 
mechanisms involved in the THD. 
 
COMPOUND BIO-ACTIVATION AND AVAILABILITY IN VITRO 
In addition to compounds directly interfering with different endpoints of the TH system, 
other THDCs such as PCBs and PBDEs require metabolic activation to become able to 
interfere with the TH signaling. This bio-activation into hydroxylated metabolites (OH-
metabolites) typically occurs in vivo by phase I enzymes (Morse and Brouwer, 1995; 
Marsh et al., 2006). These OH-metabolites can show remarkable structural similarities to 
THs and interfere with the TH homeostasis by mimicking T4 and to a lesser extent T3 
(Meerts et al., 2002; Freitas et al., 2011). These OH-metabolites can interfere with TH 
transport, action, feedback mechanisms and metabolism. In mammals including 
humans, they bind with high affinity to specific transport proteins, such as TTR and TBG 
(Lans et al., 1994; Meerts et al., 2000; Marchesini et al., 2008; Gutleb et al., 2010) and can 
accumulate in blood plasma reaching levels up to 30 times higher as compared to their 
respective parent compounds (Sjodin et al., 2000; Gebbink et al., 2008). Furthermore, the 
TH-like OH-metabolites can be selectively transported over the placenta and blood brain 
barrier (Morse et al., 1993; Meerts et al., 2002). Given the high plasma levels and the 
toxicological relevance of these metabolites, it is crucial to include the quantification of 
their toxic potencies for toxicological risk and hazard assessment. However, since most 
cell-based in vitro test systems lack phase I metabolism, the bio-activation of such 
chemicals is performed prior to testing by typically using in vitro biotransformation 
techniques with microsomal fractions. Unfortunately this approach is susceptible to low 
biotransformation efficiencies, the remaining parent compound at toxic concentrations in 
the extracts and the presence of interfering matrix components co-extracted from the 
metabolizing system (Meerts et al., 2000; Schriks et al., 2006; Hamers et al., 2008). 
Recently, a new method has been developed to separate the OH-metabolites from their 
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parent compounds followed by a non-destructive cleanup which removes potentially 
interfering matrix compounds such as microsomal fatty acids from the extract (Montano 
et al., 2012). Alternatively, an in vitro system can be exposed directly to the metabolite of 
interest, if known and available from other sources. 
In a recent study (Gutleb et al., 2012) the cellular localization of halogenated 
compounds and their OH-metabolites was visualized and their concentration 
estimated via secondary ion mass spectrometry. Relative intracellular concentrations 
of 4-OH-BDE69 and 4-OH-BDE121 in GH3.TRE.Luc cells were 61% and 18%, 
respectively, compared to the parent compounds. These differences could be due to 
phase II metabolism followed by excretion from the cells, and may partly explain the 
usually higher observed effect concentrations of the 4-OH-BDEs in in vitro cell models 
than what would be expected based on receptor binding studies. Therefore, it is 
crucial to characterize the phase II and cellular efflux mechanisms in these cell-based 
systems, as hydroxylated compounds may undergo rapid phase II metabolism and 
excretion from the cells resulting in false negative results for the testing of their 
implicit TH activities but possibly adequately defining their in vivo activity. 
 
APPLICATION OF IN VITRO TESTS IN A TESTING STRATEGY 
The TR mediated reporter gene assays developed in this thesis are suitable to be 
applied in a battery of non-animal tests for THD hazard assessment. While 
minimizing the risk of false negatives this in vitro approach should enable the 
prioritization of chemicals that need further studies. With a pathway-based chemical 
hazard assessment, both laboratory testing facilities and regulatory bodies should be 
able to focus on those chemicals of highest concern. Thus, the first function of a 
comprehensive battery of in vitro tests is to rank the thousands of poorly characterized 
chemicals. Recently an international workgroup of experts has advised a set of 
endpoints covering the most important mechanisms of the TH system regulation that 
are currently known to be sensitive for THDCs and are currently or in the near future 
applicable in an in vitro HTS test battery (Murk et al., 2012). In this Tier 1 testing 
proposal, the GH3.TRE-Luc assay is included as a promising in vitro functional assay 
suitable for this HTS platform. It is important that this, and any other in vitro 
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approaches developed, include phase I metabolism to detect possible bio-activation of 
compounds. The GH3 cells used to create the stably transfected GH3.TRE-Luc cell line 
did not show any cytochrome P4501A activity (Gutleb et al., 2005; Schriks et al., 2006), 
although one study has reported a PCB inducible P4501A1 activity for their GH3 
variant (Gauger et al., 2007). Alternatively, compounds of interest could also be pre-
incubated with microsomes to allow activation before exposure. However, it is still 
not completely clear to what extent the metabolites can reach the same intracellular 
levels as the parent compounds, since reduced uptake or phase II metabolism and 
subsequent cellular elimination could also play a role (Gutleb et al., 2010). As 
described in Chapter 2 the cellular uptake of the active metabolites when produced 
outside the TH responsive cell could be the limiting factor in an in vitro cell system in 
contrast to in vitro binding assays. Therefore, intracellular bio-activation of potential 
THDCs seems to be a prerequisite that still needs to be further developed. 
 
COMPUTATIONAL MODELING TO INTERPRET IN VITRO ASSAYS FOR IN VIVO EFFECTS 
Although it was beyond the scope of this thesis to develop an assay to be able to 
predict in vivo effects, in a later stage this could be further developed for the assays 
here created in combination with other selected assays. Despite the many advantages 
of an in vitro testing battery, estimating in vivo toxicity from in vitro results can be a 
daunting task as it is not possible to fully reproduce in vitro the complexity of a 
complete in vivo system. The absence of whole-body pharmacokinetic processes 
(absorption, distribution, metabolism and excretion) in the in vitro assay system is one 
of the main challenges in implementing in vitro based risk assessments for chemicals. 
Integration of data on the toxic mode of action of a chemical with data on its 
pharmacokinetic behavior is essential for the interpretation of in vitro toxicity studies 
of a compound for the whole animal. With physiologically based kinetic (PBK) 
models, a better interpretation of the in vivo relevance of in vitro results can be 
obtained by converting an in vitro concentration-response curve to an in vivo dose-
response curve. These approaches are also known as in vitro to in vivo extrapolation 
(IVIVE) or reverse dosimetry (Verwei et al., 2006; Forsby and Blaauboer, 2007; Louisse 
et al., 2010; Punt et al. 2012). IVIVE is the process of estimating the environmental 
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exposures to a chemical that could produce tissue exposures at the site of toxicity in 
humans equivalent to those associated with effects in an in vitro toxicity test (e.g., an 
EC50, a Benchmark concentration, etc.). IVIVE can provide an estimate of the 
likelihood of harmful effects from expected environmental exposures to chemicals by 
integrating diverse information from targeted in vitro toxicity and kinetic assays using 
a computational modeling approach. Pharmacokinetic modeling plays a pivotal role 
in this quantitative extrapolation, by incorporating the in vivo absorption, distribution, 
metabolism and excretion of the chemical into the process. 
In conclusion the results of the present thesis contribute to the further establishment 
of a battery of in vitro tests for the hazard identification of thyroid active compounds. 
Further implementation of the in vitro assays in risk assessment practice requires 
several future perspectives to be considered, including the following items: 
1. To be able to make the step from hazard to risk assessment based on in vitro test 
batteries more fundamental knowledge is needed to reveal the relationship between 
critical pathway perturbations, timing, physiological effects and diseases. With insight 
in new mechanisms, in vitro test battery results offer more possibilities to predict what 
compounds are relevant for specifically sensitive groups or conditions. This approach 
may include development of libraries of model compounds defining their behaviour 
in series of in vitro tests, enabling the identification of the mode of action of unknown 
compounds based on their patterns of results in this test battery and comparison to 
the data base in the library. 
2. Many environmental pollutants have shown to disrupt the thyroid hormone 
homeostasis. A few, as also demonstrated by the results of the present thesis, have 
shown to directly interfere with the TR. This indicates that in vitro assays for several 
other endpoints of the thyroid hormone signalling should be developed and included 
in the battery of tests. Several endpoints have so far been difficult to be modelled in in 
vitro assays, such as for example thyroid hormone synthesis and excretion. These 
endpoints do require further attention and may need more complex in vitro systems 
than just one-dimensional cell models. 
3. Comparing in vitro and in vivo responses can help to more specifically determine 
mechanisms of THD of compounds and assist the further development of models that 
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can be used in a more predictive way for regulatory toxicology. Defining relationships 
between in vitro and in vivo data will also support further validation of the integrated 
test battery and the library based on its results. 
4. When making in vitro-in vivo comparisons, it is important to consider not only 
external doses but also consider the blood plasma levels (internal concentrations) of 
the compounds and/or its bioactive metabolites in the in vivo experiments. PBK 
modeling may be a way to provide this information and make the link between in 
vitro concentration response curves and in vivo dose response data. 
5. Since the development of PBK models for a single compound requires a significant 
amount of research, efforts should be undertaken to further develop general PBK 
model approaches for series of (related) compounds, possibly using (quantitative) 
structure activity ((Q)SAR) approaches to define the required parameters and/or the 
use of simple general PBK models as used in ToxCast. 
6. Elucidation of the relative importance of the so-called non-genomic TH action and 
whether these are relevant targets for TH disrupting chemicals and hence assay 
development is an underinvestigated topic that deserves further attention. 
7. Further development of these future perspectives would provide important 
further contributions to toxicity testing in the 21st century (Testing and Assessment of 
Environmental Agents, 2007) and the development of an integrated testing strategy 
for thyroid active compounds adding additional value to the assays aiming at 
replacement of animal studies developed in the framework of the present thesis. 
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et doel van de voorliggende thesis was het ontwikkelen van functionele in 
vitro bioassays voor het opsporen van stoffen die invloed hebben op het 
schildklierhormoonsysteem op het niveau van de schildklierhormoonreceptor. 
De te ontwikkelen assays moesten geschikt zijn voor zogenoemde “quantitative high-
troughput screening” (qHTS) en moesten in te passen zijn in een in vitro-testreeks die 
gebruikt kan worden als vervanging voor dierproeven bij de identificatie van 
schildklierhormoonverstorende stoffen en kwantificering van hun sterkte. 
In Hoofdstuk 1 wordt achtergrondinformatie gegeven en worden de doelen van dit 
proefschrift gepresenteerd. Om te beginnen wordt uitgelegd dat het schildklier-
hormoonsysteem verantwoordelijk is voor meerdere belangrijke fysiologische 
processen, zoals regulering van de energiehuishouding, groei en differentiatie, 
ontwikkeling en onderhoud van de hersenfunctie, warmteregeling, osmoseregulering, 
het in werking stellen en goed functioneren van andere endocriene systemen, seksueel 
gedrag en vruchtbaarheid en cardiovasculaire functies. Het belang van het 
schildklierhormoonsysteem en de zorgen over verstoring ervan hebben geresulteerd 
in de ontwikkeling van in vitro-strategieën om schildklierhormoon-verstorende 
stoffen te identificeren. Deze informatie wordt doorgaans aan de hand van dierstudies 
verkregen en is, voor wat betreft de meeste chemische stoffen die in het milieu 
aanwezig zijn, nogal beperkt of niet beschikbaar. Om ethische, financiële en 
praktische redenen zijn in vitro- en in silico-alternatieven cruciaal voor de herkenning 
van schildklierhormoonverstorende stoffen en voor de kwantificering van hun 
effecten. Verstoring van de schildklierhormoonfunctie kan optreden via verschillende 
mechanismen, zoals veranderingen in hormoonproductie, transport, stofwisseling, 
receptoractivering en verstoring van terugkoppelingsmechanismen. Voor verschillen-
de –zij het niet voor alle- van deze eindpunten zijn al in vitro-assays beschikbaar. Op 
het moment van het begin van dit onderzoek was er geen functionele in vitro bioassay 
beschikbaar voor het opsporen van schildklierhormoonreceptor-agonisten en -
antagonisten die ook geschikt zouden zijn voor qHTS van potentiële schildklierhor-
moonverstorende stoffen. Daarom was het doel van het huidige onderzoek 
H 
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functionele in vitro bioassays te ontwikkelen en te valideren voor schildklierhormoon 
receptor-gemedieerde toxiciteit, toegespitst op de receptorinteractie van het 
schildklierhormoon. 
Hoofdstuk 2 beschrijft de ontwikkeling van een stabiele luciferase reporter gen assay, 
gebaseerd op de schildklierhormoon responsieve rat hypofyse tumor GH3 cellijn die 
structureel beide schildklierhormoonreceptoren laat zien, waarbij TR! de 
belangrijkste schildklierhormoonreceptor blijkt te zijn. De assay werd ontwikkeld 
door stabiele transfectie van het pGL4CP-SV40-2xtaDR4 construct in de GH3-cellen, 
resulterend in een zeer gevoelige schildklierhormoon cellijn (GH3, TRE-Luc), die 
verder werd geoptimaliseerd in een assay waarmee de detectie werd bewerkstelligd 
van triidothyronine- (T3) en thyroxine- (T4) concentraties in het picomolaire gebied na 
slechts 24 uur blootstelling. De meer dan 20-voudige inductie door T3 ten opzichte van 
de controle met het oplosmiddel, is illustratief voor de hoge gevoeligheid van het 
systeem. De assay werd gevalideerd door de kwantificering van het agonistisch effect 
van de natuurlijke hormonen (T3 en T4), de azijnzuurderivaten van T3 (triiodothyro-
acetic acid, Triac) en T4 (tetraidodothyroacetic acid, Tetrac), hydroxypolybrominated 
diphenylethers (OH-PBDEs), hydroxypolychlorinated biphenyls (OH-PCBs) en de 
antagonistische actie van natriumarseniet (NaAsO2). De mogelijke antagonisten 
amiodarone en bisphenol A (BPA) en de gehalogeneerde derivaten daarvan (TCBPA 
en TBBPA), waarvan de in de literatuur beschreven effecten niet consistent zijn, 
vertoonden vergelijkbare dosis-respons curves met een gering agonistisch effect (5% 
van T3-max). De omvang en reproduceerbaarheid van de responses op diverse stoffen 
bevestigden dat de assay een veelbelovende techniek is voor de identificatie en het 
kwantificeren van specifieke schildklierhormoonreceptor actieve stoffen. 
In hoofdstuk 3 wordt het gebruik beschreven van de GH3.TRE-Luc reporter gen 
cellijn in een qHTS platform. De GH3.TRE-Luc assay werd gemodificeerd en 
gevalideerd voor gebruik van de kleinere volumes, geschikt voor het formaat van een 
1536-wells plaat. Door dit sterk verkleinde formaat te gebruiken, werd het mogelijk de 
collecties van de Library of Pharmacologically Active Compounds (LOPAC) en de 
National Toxicology Program (NTP) collectie te screenen op schildklierhormoon-
receptoragonisten en -antagonisten. Van de 2688 stoffen die werden getest, werden er 
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8 of 1 als TR-agonisten geïdentificeerd -afhankelijk van de definitie van de positieve 
cut off- hetzij op ≥10%, hetzij op ≥20% van werkzaamheid in verhouding tot T3, en 5 
stoffen werden geïdentificeerd als antagonisten. Geen van de niet-actieve stoffen was 
structureel verwant aan T3, en ook bij verdere structurele analyse van de geteste 
stoffen werd geen schildklierhormoonverstorende stof ontdekt. De lage-potentie 
agonisten leken ook niet op de schildklierhormonen, wat een aanwijzing is dat deze 
niet direct actief zijn via het ligand-binding gebied van de receptor en dat ze mogelijk 
geen effectieve agonisten zijn. Het bepalen van schildklierhormoonreceptor agonisten 
in de qHTS, waarbij gebruik wordt gemaakt van de criteria van een hit cut off van 
≥20% werkzaamheid bij 100 #M, zou identificatie kunnen voorkómen van positieven 
zonder fysiologische relevantie. Geconcludeerd werd dat de verkleinde GH3.TRE-Luc 
assay een belangrijke aanvulling is op de testreeks voor schildklierhormoonreceptor-
gemedieerde endocriene verstoring en dat, gezien het lage percentage van positief 
geteste stoffen, zijn high-throughput karakter een groot voordeel is voor toekomstige 
toxicologische screening. 
Nadat de GH3.TRE-Luc cellen hoog-responsief bleken te zijn en geschikt voor de 
toepassing in een qHTS testreeks voor het opsporen van schildklierhormoon-
verstorende chemicaliën, werd een vergelijking gemaakt met de respons van 
betrouwbare endogene schildklierhormoon doelgenen (Hoofdstuk 4). In aanvulling 
op de TRE-gestuurde luciferase inductie in de GH3.TRE-Luc cellen, werd ook 
schildklierhormoonafhankelijke celproliferatie geanalyseerd, omdat het effect van 
sommige schildklierhormoonverstorende stoffen onafhankelijk kon zijn van de 
geldende schildklierhormoon gemedieerde effecten op genexpressie. In deze studie 
werden GH3 cellen behandeld zowel met T3 als met twee schildklierhormoonreceptor 
vormen (TR$ and TR!) selectieve thyromimetics,  respectievelijk CO23 en GC-1. 
Responsprofielen in de reportergen assay vertoonden uitstekende overeenkomst met 
endogene groeihormoon (GH) genexpressie, een bekend direct schildklierhormoon 
doelgen en de basis van het gebruik van deze cellen in de op celproliferatie 
gebaseerde T-screen. Voorts werd duidelijk dat natriumarseniet, bisphenol A en de 
phtalate DEHP de T3 gemedieerde inductie van het reportergen onderdrukken evenals 
de endogene expressie van het GH-gen. Een daaropvolgend uitgevoerd microarray 
Chapter 7 
 184 
experiment bracht een vollediger spectrum aan het licht van de T3 respons-genen in 
deze cellen. Naast het identificeren van verscheidene belangrijke componenten van de 
schildklierhormoon-signaling pathway, maakte de microarray de identificatie 
mogelijk van een reeks van zowel reeds bekende als van nieuwe schildklierhormoon 
doelgenen, inclusief genen die gerelateerd zijn aan angiogenese zoals HIF2$ 
(ERPAS1). Identificatie van deze genen is belangrijk voor de validatie van assays die 
ontworpen zijn om nieuwe synthetische schildklierhormoonreceptor modulatoren en 
hun potentiële genomische, versus non-genomische modes of action te identificeren. 
Hoofdstuk 5 gaat over de kritische rol van het schildklierhormoon in processen zoals 
hersenontwikkeling, groei en energie-homeostase die plaats vinden via verschillende 
vormen van de schildklierhormoonreceptor. Omdat de belangrijkste vormen, TR$ 
and TR!, onderscheiden fysiologische functies representeren, is het belangrijk de 
schilklierhormoonreceptor specifieke potentie van schildklierhormoon actieve stoffen 
te bestuderen. Dit hoofdstuk beschrijft de ontwikkeling van TR$- and TR!- 
gebaseerde reporter gen bioassays die humane cervicale HeLa-cellen gebruiken en zo 
kwantificering mogelijk maken van de respons van de schildklierhormoonreceptor 
vorm-selectieve chemicaliën CO23 en GC-1. In combinatie hiermee werd een stabiele 
TR$-specifieke gen cellijn ontwikkeld,  die de naam TR$.HeLa-Luc kreeg.  Reacties in 
deze  TR$.HeLa-Luc cellijn werden vergeleken met reacties in de GH3.TRE-Luc-
cellijn, die TR! bleek te bevatten als belangrijkste schildklierhormoon receptorvorm. 
De schildklierhormoonreceptor-selectieve chemicaliën CO23 en GC-1 veroorzaakten 
reacties overeenkomend met de verwachte potentierangorde T3>GC-1>CO23 in de 
TR$.HeLa-Luc-cellijn en T3>CO23>GC-1 in de GH3.TRE-Luc-cellijn. In aanvulling op 
de 7 bekende schildklierhormoonreceptor actieve standaarden werden 10 chemicaliën 
getest die ervan verdacht werden dat zij een schildklierhormoonreceptor verstorende 
werking zouden hebben. Van deze chemicaliën veroorzaakten alleen natriumarseniet 
en de T3-achtige 4-OH-BDE69 een reactie in de TR$.HeLa-Luc assay. Samen voegen 
de ontwikkelde TR$.HeLa-Luc en de GH3.TRE-Luc stabiele reportergen cellijnen een 
nieuw niveau van specificiteit toe aan de bestaande testreeks en bewerkstelligen 
daarmee een verbetering van de beschikbare tools voor in vitro high throughput 
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assessment van schildklierhormoonreceptor specifieke activiteit van geneesmiddelen 
en milieuverontreinigende stoffen. 
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